Lipid-modified nucleic acid compounds and methods

Lipid-modified nucleic acid compounds enhance cellular uptake and functional activity of therapeutic nucleic acids, addressing the challenge of efficient delivery by utilizing specific linkers and lipid conjugates.

JP7583712B2Active Publication Date: 2024-11-14NOVARTIS AG
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2021516851
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-01-17
Filing Date
2019-05-30
Publication Date
2024-11-14
Estimated Expiration
2039-05-30

AI Technical Summary

Technical Problem

Delivering therapeutic nucleic acids to cells remains a challenging area of research, necessitating improved nucleic acid compounds and strategies for efficient cellular uptake.

Method used

Development of lipid-modified nucleic acid compounds, including structures with specific linkers and lipid conjugates, for enhanced cellular uptake under free uptake conditions without the need for transfection reagents.

Benefits of technology

The lipid-modified nucleic acid compounds demonstrate effective intracellular delivery and functional activity of therapeutic nucleic acids, as evidenced by reduced mRNA expression levels in various cell types.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583712000209
    Figure 0007583712000209
  • Figure 0007583712000210
    Figure 0007583712000210
  • Figure 0007583712000211
    Figure 0007583712000211
Patent Text Reader

Abstract

In particular, disclosed herein are lipid-modified nucleic acid compounds having the following structure, their preparation, and their uses: (I)
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Patent Application No. 62 / 678,013, filed May 30, 2018, and U.S. Provisional Patent Application No. 62 / 793,597, filed January 17, 2019, which are incorporated herein in their entireties for all purposes.

[0002] A reference to a "Sequence Listing", a table, or a computer program listing appendix submitted as an ASCII file The sequence listing set forth in file 052974-502001WO_ST25.TXT (3,449 bytes, machine format IBM-PC, MS Windows operating system), created on May 23, 2019, is incorporated herein by reference.

[0003] The present disclosure relates to the field of biologically active nucleic acid compounds. More specifically, the present disclosure relates to lipid-modified nucleic acid compounds, their preparation, and their use. [Background technology]

[0004] Delivering therapeutic nucleic acids to cells remains a challenging area of ​​research. Thus, there is a need for improved nucleic acid compounds and strategies for introducing such compounds into cells. Summary of the Invention

[0005] In particular, provided herein is a compound, or lipid-modified nucleic acid compound, having the structure: [ka]

[0006] A is an oligonucleotide, a nucleic acid, a polynucleotide, a nucleotide or analog thereof, or a nucleoside or analog thereof. In an embodiment, A is an oligonucleotide. In an embodiment, A is a nucleic acid. In an embodiment, A is a polynucleotide. In an embodiment, A is a nucleotide or analog thereof. In an embodiment, A is a nucleoside or analog thereof.

[0007] L 3 and L 4 each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0008] L 5 -L 5A -L 5B -L 5C -L 5D -L 5E - and L 6 -L 6A -L 6B -L 6C -L 6D -L 6E -It is. 5A , L 5B , L 5C , L 5D , L 5E , L 6A , L 6B , L 6C , L 6D , and L 6Eare independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0009] R 1 and R 2 independently, unsubstituted C 1 -C 25 alkyl, where R 1 and R 2 At least one of the groups is unsubstituted C 9 -C 19 is alkyl, R 3 is hydrogen, -NH 2 , -OH, -SH, -C(O)H, -C(O)NH 2 , -NHC(O)H, -NHC(O)OH, -NHC(O)NH 2 , -C(O)OH, -OC(O)H, -N 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0010] t is an integer from 1 to 5.

[0011] In embodiments, a lipid-conjugated compound having the structure of Formula I: [ka] or a pharma- ceutically acceptable salt thereof, 1 and m has any of the values ​​described herein.

[0012] In embodiments, a lipid-conjugated compound having the structure of Formula II: [ka] Provided herein are compounds, wherein A has any of the values ​​described herein, or a pharma- ceutically acceptable salt thereof.

[0013] In embodiments, a lipid-conjugated compound having the structure of Formula III: [ka] or a pharma- ceutically acceptable salt thereof, 1 and Z 2 Provided herein are compounds, wherein R has any of the values ​​described herein.

[0014] In embodiments, provided herein are cells containing the compounds disclosed and described herein.

[0015] In embodiments, provided herein is a method of introducing a modified double-stranded oligonucleotide into a cell in vitro, comprising contacting the cell with a compound disclosed and described herein under free uptake conditions.

[0016] In embodiments, provided herein is a method of introducing a modified double-stranded oligonucleotide ex vivo, comprising contacting a cell under free uptake conditions with a compound as disclosed and described herein. [Brief description of the drawings]

[0017] [Figure 1] The structure of the synthesized DHA-conjugated siRNA is shown. [Diagram 2] The structure of the synthesized DTx-01-08 conjugated siRNA is shown. [Diagram 3] 1 shows the structure of PTEN siRNA synthesized with C10-C22 saturated fatty acids attached. [Figure 4]The structure of the synthesized C16 LCFA-conjugated siRNA is shown. [Diagram 5] 1 shows the structure of PTEN siRNA synthesized with LCFA conjugation at both the 3' and 5' positions. [Figure 6] 1 shows the structure of PTEN siRNA synthesized with a conjugated C16 LCFA containing a terminal COOH group. [Figure 7] 1 shows the structures of synthesized DTx-01-08 conjugates DTxO-0038, DTxO-0033, and DTXO-0034 siRNAs. [Figure 8] 1 shows the structure of DTxO-0003 siRNA conjugated to a motif having one or more unsaturated LCFAs. [Figure 9] 1 shows the structure of DTxO-0003 siRNA conjugated to a motif with a rigid linker. [Figure 10] 1 shows the structure of DTxO-0003 siRNA conjugated to a motif having three LCFAs. [Figure 11] 1 shows the structures of DTxO-0003 siRNA or DTxO-0038 siRNA conjugated to the DTx-01-08 motif at the 5' end of the passenger strand or the 3' end of the guide strand. [Figure 12A] 1 shows the structure of DTxO-0003 siRNA conjugated to a DTx-01-50, DTx-01-51, DTx-01-52, DTx-01-53, DTx-01-54, or DTx-01-55 motif. [Figure 12B] 1 shows the structure of DTxO-0003 siRNA conjugated to a DTx-03-50, DTx-03-51, DTx-03-52, DTx-03-53, DTx-03-54, or DTx-03-55 motif. [Figure 12C] 1 shows the structure of DTxO-0003 siRNA conjugated to a DTx-06-50, DTx-06-51, DTx-06-52, DTx-06-53, DTx-06-54, or DTx-06-55 motif. [Figure 13] Shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 7, 8, 26, and 1 for 48 hours compared to PBS control. [Figure 14] 1 shows the percentage of PTEN mRNA expression in HEK293 cells compared to PBS control after exposing the cells to various concentrations of compounds 2, 7, 8, 26, and 1 for 48 hours under free uptake conditions. [Figure 15] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of the cells to various concentrations of compounds 2, 7, 8, 26, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 16] 1 shows a comparison of the effects of conjugates containing a rigid linker structure or three LCFAs on PTEN mRNA expression after compound transfection into HEK293 cells for 48 hours. [Figure 17] 1 shows a comparison of the effects of conjugates containing a rigid linker structure or three LCFAs on PTEN mRNA expression after free uptake of the compounds into HUVEC cells for 48 hours. [Figure 18] 1 shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 9, and 1 for 48 hours compared to PBS control. [Figure 19] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposing the cells to various concentrations of compounds 2, 9, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 20] Shown is the effect of compounds having conjugate moieties attached to the 5' or 3' end of the passenger strand of two different siRNAs after transfection into HEK293 cells for 48 hours. [Figure 21] The effects of compounds with conjugate moieties attached to the 5' or 3' end of the passenger strand of two different siRNAs are shown after free uptake into HUVEC cells for 48 hours. [Figure 22] 1 shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 25, 24, and 1 for 48 hours compared to PBS control. [Diagram 23] 1 shows the percentage of PTEN mRNA expression in NIH3T3 cells after transfection with various concentrations of compounds 2, 25, 24, and 1 for 48 hours compared to PBS control. [Figure 24] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposing the cells to various concentrations of compounds 2, 25, 24, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Diagram 25] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of cells to various concentrations of compounds 2, 25, 24, and 1 for 96 hours under free uptake conditions, compared to PBS control. [Figure 26] 1 shows the percentage of PTEN mRNA expression in HEK293 cells compared to PBS control after exposing the cells to various concentrations of compounds 2, 25, 24, and 1 for 48 hours under free uptake conditions. [Figure 27] 1 shows the percentage of PTEN mRNA expression in HEK293 cells compared to PBS control after exposure of cells to various concentrations of compounds 2, 25, 24, and 1 for 96 hours under free uptake conditions. [Figure 28] 1 shows the percentage of PTEN mRNA expression in NIH3T3 cells compared to PBS control after exposure of cells to various concentrations of compounds 2, 25, 24, and 1 for 48 hours under free uptake conditions. [Figure 29] 1 shows the percentage of PTEN mRNA expression in NIH3T3 cells compared to PBS control after exposure of cells to various concentrations of compounds 2, 25, 24, and 1 for 96 hours under free uptake conditions. [Diagram 30] 1 shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 20, 21, and 23 for 48 hours compared to PBS control. [Diagram 31] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of the cells to various concentrations of compounds 1, 2, 20, 21, and 23 for 48 hours under free uptake conditions, compared to PBS control. [Diagram 32] 1 shows a comparison of the effects of conjugates containing saturated or unsaturated fatty acids on PTEN mRNA expression following transfection into HEK293 cells. [Diagram 33] 1 shows a comparison of the effects of conjugates containing saturated or unsaturated fatty acids on PTEN mRNA expression after free uptake into HUVEC cells. [Diagram 34] Shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 10, 11, 12, and 1 for 48 hours compared to PBS control. [Diagram 35] 1 shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 13, 14, 15, and 1 for 48 hours compared to PBS control. [Diagram 36] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of the cells to various concentrations of compounds 2, 10, 11, 12, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 37] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of cells to various concentrations of compounds 2, 13, 14, 15, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 38] 1 shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 16, 17, 18, and 1 for 48 hours compared to PBS control. [Figure 39] 1 shows the percentage of PTEN mRNA expression in HEK293 cells compared to PBS control after exposing the cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 48 hours under free uptake conditions. [Diagram 40]1 shows the percentage of PTEN mRNA expression in differentiated SH-SY5Y cells after exposing the cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Diagram 41] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Diagram 42] 1 shows the percentage of PTEN mRNA expression in HUVEC cells compared to PBS control after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 96 hours under free uptake conditions. [Diagram 43] 1 shows the percentage of PTEN mRNA expression compared to PBS control in primary rat neurons after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 for 96 hours under free uptake conditions. [Diagram 44] 1 shows the percentage of PTEN mRNA expression compared to PBS control in primary rat neurons after exposure of cells to various concentrations of compounds 2, 16, 17, 18, and 1 under free uptake conditions for 7 days. [Figure 45A] 1 shows the percentage of VEGFR1 expression in HUVEC cells after transfection with various concentrations of compounds 3 and 1 for 48 hours compared to PBS control. [Figure 45B] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after transfection with various concentrations of compounds 3 and 1 for 48 hours compared to PBS control. [Figure 46A] 1 shows the percentage of VEGFR2 expression in HUVEC cells after transfection with various concentrations of compounds 5 and 1 for 48 hours compared to PBS control. [Figure 46B] The percentage of PTEN in HUVEC cells after transfection with various concentrations of compounds 5 and 1 for 48 hours is shown compared to PBS control. [Figure 47]1 shows the percentage of VEGFR1 mRNA expression in HUVEC cells after exposure of the cells to various concentrations of compounds 4 and 3 for 48 hours under free uptake conditions, compared to PBS control. [Figure 48] Figure 1 shows the percentage of VEGFR2 mRNA expression in HUVEC cells after exposure of the cells to various concentrations of compounds 6 and 5 for 48 hours under free uptake conditions, compared to PBS control. [Figure 49] 1 shows the percentage of HTT mRNA expression in differentiated SH-SY5Y cells after transfection with various concentrations of compounds 29, 28, 27, 2, and 1 for 48 hours compared to PBS control. [Figure 50] 1 shows the percentage of HTT mRNA expression in undifferentiated SH-SY5Y cells compared to PBS control after exposing the cells to various concentrations of compounds 29, 28, 27, 2, and 1 for 48 hours under free uptake conditions. [Figure 51] 1 shows the percentage of HTT mRNA expression in differentiated SH-SY5Y cells after exposing the cells to various concentrations of compounds 29, 28, 27, 2, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 52] Figure 1 shows the percentage of PTEN mRNA expression in differentiated 3T3L1 adipocytes after exposure of cells to various concentrations of compounds 2 and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 53] The percentage of PTEN mRNA expression in the trabecular meshwork after 48 hours of exposure of cells to various concentrations of compounds 2 and 1 under free uptake conditions is shown compared to PBS control. [Figure 54] 1 shows the percentage of PTEN mRNA expression in differentiated primary human skeletal muscle cells after exposure of cells to various concentrations of compounds 2 and 1 for 96 hours under free uptake conditions, compared to PBS control. [Figure 55] 1 shows the percentage of PTEN mRNA expression in primary human hepatocytes after exposure of cells to various concentrations of compounds 1, 2, 7, 8, and 9 for 48 hours under free uptake conditions, compared to PBS control. [Figure 56]Shown is the percentage of PTEN mRNA expression for compounds 1, 2, 7, 8, and 9 compared to PBS control in primary human adipocytes after 7 days of incubation. [Figure 57] 1 shows the percentage of PTEN mRNA expression in differentiated primary human skeletal muscle cells after exposure of cells to various concentrations of compounds 1, 2, 7, 8 and 9 for 96 hours under free uptake conditions, compared to PBS control. [Figure 58] 1 shows the percentage of PTEN mRNA expression compared to PBS control in primary human astrocytes after exposure of cells to various concentrations of compounds 1, 2, 7, 8, and 9 for 48 hours under free uptake conditions. [Figure 59] 1 shows the percentage of PTEN mRNA expression in human T cells after exposure of cells to various concentrations of compounds 2 and 9 for 96 hours under free uptake conditions, compared to PBS control. [Figure 60] 1 shows the percentage of PTEN mRNA expression 7 days after intravitreal injection of Compound 2 and Compound 37 in mice at various doses. [Figure 61] Quantitative in situ hybridization (RNAscope) is shown 7 days after intravitreal injection of Compound 2 in rats. (ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; 10x, 10x magnification; 40x, 40x magnification). [Figure 62] The percentage of PTEN mRNA expression 7 days after intravitreal injection of Compound 2 in rats is shown. [Figure 63] Shows the percentage of PTEN mRNA expression after transfection of HEK293 cells with conjugated (compound 2) and unconjugated (compound 30) PTEN siRNA at various doses for 48 hours. [Figure 64] Percentage of mRNA expression 7 days after intravitreal injection of Compound 2 and Compound 33 in mice (One-way ANOVA, Tukey Post-hoc, ***p<0.001, ****p<0.0001, NS, not significant). [Figure 65]Percentage of HTT mRNA expression 7 days after intravitreal injection of Compound 2 and Compound 29 in mice (One-way ANOVA, Tukey Post-hoc, *p<0.05, ****p<0.0001, NS, not significant). [Figure 66] 1 shows the percentage of VEGFR2 mRNA expression after transfection of BEND cells with unconjugated VEGFR2 siRNA (compounds 31 and 32) at various doses for 48 hours. [Figure 67] Figure 1 shows the percentage of VEGFR2 mRNA expression 7 days after intravitreal injection of compounds 2, 34 and 35 in mice (One-way ANOVA, Tukey Post-hoc, ***p<0.001, ****p<0.0001, NS, not significant). [Figure 68] Figure 1 shows the percentage of VEGFR2 mRNA expression 7 days after intravitreal injection of compounds 2 and 34 in rats. (One-way ANOVA, Tukey Post-hoc, ****p<0.0001, NS, not significant). [Figure 69] Figure 1 shows the percentage of PTEN mRNA expression 7 days after intravitreal injection of mice with compounds 2, 20, 21 and 1. (One-way ANOVA, Tukey Post-hoc, ***p<0.001, ****p<0.0001, NS, not significant). [Figure 70] Figure 1 shows the percentage of PTEN mRNA expression 7 days after intravitreal injection of mice with Compounds 11, 12, 2, 13, and Compound 1. (One-way ANOVA, Tukey Post-hoc, **p<0.01, ****p<0.0001, NS, not significant). [Figure 71] The percentage of PTEN mRNA expression 7 days after intravitreal injection of compounds 1 and 2 in mice is shown. [Figure 72] PTEN mRNA expression in the liver of C57Bl / 6 mice 7 days after subcutaneous (SQ) or intravenous (IV) administration of Compound 33. [Figure 73]PTEN mRNA expression in muscle, heart, adipose, lung, liver, kidney, and spleen tissues 7 days after intravenous administration of Compound 33 to C57Bl / 6 mice. [Figure 74] Shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 12, 54, 55, and 1 for 48 hours compared to PBS control. [Figure 75] Shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 2, 13, 56, 57, and 1 for 48 hours compared to PBS control. [Figure 76] 1 shows the percentage of PTEN mRNA expression in HEK293 cells after transfection with various concentrations of compounds 12, 13, 58, 59, and 1 for 48 hours compared to PBS control. [Figure 77] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of cells to various concentrations of compounds 2, 12, 54, 55, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 78] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of cells to various concentrations of compounds 2, 13, 56, 57, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 79] 1 shows the percentage of PTEN mRNA expression in HUVEC cells after exposure of cells to various concentrations of compounds 12, 13, 58, 59, and 1 for 48 hours under free uptake conditions, compared to PBS control. [Figure 80] 1 shows the structures of compounds 72-83, which have various combinations of saturated and unsaturated long chain fatty acid motifs conjugated to the 3′ end of the passenger strand of siRNA. [Figure 81] 1 shows the structures of compounds 84-95, which have various combinations of saturated and unsaturated long chain fatty acid motifs conjugated to the 3′ end of the passenger strand of siRNA. [Figure 82]1 shows the structures of compounds 96-107, which have various combinations of saturated and unsaturated long chain fatty acid motifs conjugated to the 3′ end of the passenger strand of an siRNA. [Figure 83] 1 shows the structures of compounds 108-113, which have various combinations of saturated and unsaturated long chain fatty acid motifs conjugated to the 3′ end of siRNA. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] definition Unless otherwise defined, all technical terms, scientific terms, abbreviations, chemical structures, and chemical formulas used herein have the same meaning as commonly understood by those skilled in the art. The chemical structures and formulas described herein are constructed according to the standard rules of chemical valence known in the chemical arts. All patents, applications, published applications, and other publications referenced herein are incorporated by reference in their entirety unless otherwise specified. Conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA technology, and pharmacology are used unless otherwise indicated. Furthermore, the use of the term "including" and other forms such as "include", "includes", and "comprised" is not limiting. As used herein, whether in transition phrases or in the body of the claims, the terms "comprise(s)" and "comprising" should be interpreted as having an open-ended meaning. That is, the term should be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound, composition, or device, the term "comprising" means that the compound, composition, or device includes at least the recited features or components, but may include additional features or components.

[0019] Where substituents are specified by their conventional chemical formula written from left to right, those substituents equally encompass chemically identical substituents whose structures are written from right to left (e.g., -CH 2 O- is -OCH 2 - is equivalent to

[0020] The term "alkyl," by itself or as part of another substituent, means, unless otherwise specified, a straight (i.e., unbranched) or branched carbon chain (or carbons), or combinations thereof, which may be fully saturated, mono- or polyunsaturated, and which may include mono-, di- and polyvalent groups. An alkyl can contain a specified number of carbons (e.g., C 1 -C 10 means 1-10 carbons). An alkyl is a chain that is not cyclized. Examples of saturated hydrocarbon groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, methyl, such as n-pentyl, n-hexyl, n-heptyl, n-octyl, and other homologs and isomers. Unsaturated alkyl groups are those that have one or more double or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologs and isomers. An alkoxy is an alkyl connected to the remainder of the molecule via an oxygen linker (-O-). The alkyl moiety may be an alkenyl moiety. The alkyl moiety may be an alkynyl moiety. The alkyl portion may be fully saturated. An alkenyl may contain, in addition to one or more double bonds, two or more double bonds and / or one or more triple bonds. An alkynyl may contain, in addition to one or more triple bonds, two or more triple bonds and / or one or more double bonds.

[0021] In embodiments, the term "cycloalkyl" refers to a monocyclic, bicyclic, or polycyclic cycloalkyl ring system. In embodiments, a monocyclic ring system is a cyclic hydrocarbon group containing 3 to 8 carbon atoms, and such groups may be saturated or unsaturated, but are not aromatic. In embodiments, a cycloalkyl group is fully saturated. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. A bicyclic cycloalkyl ring system is a bridged monocyclic ring or a fused bicyclic ring. In embodiments, a bridged monocyclic ring is one in which two non-adjacent carbon atoms of a monocyclic ring are joined by an alkylene bridge of 1 to 3 additional carbon atoms (i.e., of the form (CH 2 ) wwherein w is 1, 2, or 3). Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. In embodiments, the fused bicyclic cycloalkyl ring system contains a monocyclic cycloalkyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. In embodiments, the bridged or fused bicyclic cycloalkyl is connected to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkyl ring. In embodiments, the cycloalkyl group is optionally substituted with one or two groups that are independently oxo or thia. In embodiments, the fused bicyclic cycloalkyl is a 5- or 6-membered monocyclic cycloalkyl ring fused to either a phenyl ring, a 5- or 6-membered monocyclic cycloalkyl, a 5- or 6-membered monocyclic cycloalkenyl, a 5- or 6-membered monocyclic heterocyclyl, or a 5- or 6-membered monocyclic heteroaryl, where the fused bicyclic cycloalkyl is optionally substituted with one or two groups which are independently oxo or thia. In embodiments, the polycyclic cycloalkyl ring system is a monocyclic cycloalkyl ring (group ring) fused to either (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl, or (ii) two other ring systems independently selected from the group consisting of phenyl, bicyclic aryl, monocyclic or bicyclic heteroaryl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic cycloalkenyl, and monocyclic or bicyclic heterocyclyl. In embodiments, the polycyclic cycloalkyl is connected to the parent molecular moiety through any carbon atom contained within the group ring.In embodiments, the polycyclic cycloalkyl ring system is a monocyclic cycloalkyl ring (group ring) fused to either (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl, or (ii) two other ring systems independently selected from the group consisting of phenyl, monocyclic heteroaryl, monocyclic cycloalkyl, monocyclic cycloalkenyl, and monocyclic heterocyclyl. Examples of polycyclic cycloalkyl groups include, but are not limited to, tetradecahydrophenanthrenyl, perhydrophenothiazin-1-yl, and perhydrophenoxazin-1-yl.

[0022] In embodiments, cycloalkyl is cycloalkenyl. The term "cycloalkenyl" is used according to its obvious ordinary meaning. In embodiments, cycloalkenyl is a monocyclic, bicyclic, or polycyclic cycloalkenyl ring system. In embodiments, a monocyclic cycloalkenyl ring system is a cyclic hydrocarbon group containing 3 to 8 carbon atoms, such group being unsaturated (i.e., containing at least one cyclic carbon-carbon double bond), but not aromatic. Examples of monocyclic cycloalkenyl ring systems include cyclopentenyl and cyclohexenyl. In embodiments, a bicyclic cycloalkenyl ring is a bridged monocyclic ring or a fused bicyclic ring. In embodiments, a bridged monocyclic ring is a ring in which two non-adjacent carbon atoms of a monocyclic ring are joined by an alkylene bridge of 1 to 3 additional carbon atoms (i.e., of the form (CH 2 ) wThe fused bicyclic cycloalkenyl ring system contains a monocyclic cycloalkenyl ring connected by a bridging group, w, which is 1, 2, or 3. Representative examples of bicyclic cycloalkenyls include, but are not limited to, norbornenyl and bicyclo[2.2.2]oct2enyl. In embodiments, the fused bicyclic cycloalkenyl ring system contains a monocyclic cycloalkenyl ring fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocyclyl, or a monocyclic heteroaryl. In embodiments, the bridged or fused bicyclic cycloalkenyl is connected to the parent molecular moiety through any carbon atom contained within the monocyclic cycloalkenyl ring. In embodiments, the cycloalkenyl group is optionally substituted with one or two groups that are independently oxo or thia. In embodiments, the polycyclic cycloalkenyl ring contains a monocyclic cycloalkenyl ring (group ring) fused to either (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl, or (ii) two other ring systems independently selected from the group consisting of phenyl, bicyclic aryl, monocyclic or bicyclic heteroaryl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic cycloalkenyl, and monocyclic or bicyclic heterocyclyl. In embodiments, the polycyclic cycloalkenyl is connected to the parent molecular moiety through any carbon atom contained within the group ring. In embodiments, the polycyclic cycloalkenyl ring contains a monocyclic cycloalkenyl ring (base ring) fused to either (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl, or (ii) two ring systems independently selected from the group consisting of phenyl, monocyclic heteroaryl, monocyclic cycloalkyl, monocyclic cycloalkenyl, and monocyclic heterocyclyl.

[0023] In an embodiment, the heterocycloalkyl is heterocyclyl. The term "heterocyclyl" as used herein means a monocyclic, bicyclic, or polycyclic heterocycle. A heterocyclyl monocyclic heterocycle is a 3-, 4-, 5-, 6-, or 7-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S, and the ring is saturated or unsaturated but not aromatic. A 3- or 4-membered ring contains one heteroatom selected from the group consisting of O, N, and S. A 5-membered ring may contain zero or one double bond and one, two, or three heteroatoms selected from the group consisting of O, N, and S. A 6- or 7-membered ring contains zero, one, or two double bonds and one, two, or three heteroatoms selected from the group consisting of O, N, and S. A heterocyclyl monocyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the heterocyclyl monocyclic heterocycle. Representative examples of heterocyclyl monocyclic heterocycles include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1,3 dioxanyl, 1,3 dioxolanyl, 1,3 dithiolanyl, 1,3 dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isothiazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1,1 dioxidothiomorpholinyl (thiomorpholinesulfone), thiopyranyl, and trithianyl. A heterocyclyl bicyclic heterocycle is a monocyclic heterocycle fused to either a phenyl, a monocyclic cycloalkyl, a monocyclic cycloalkenyl, a monocyclic heterocycle, or a monocyclic heteroaryl. A heterocyclyl bicyclic heterocycle is connected to the parent molecular moiety through any carbon atom or any nitrogen atom contained within the monocyclic heterocycle portion of the bicyclic ring system.Representative examples of bicyclic heterocyclyl include, but are not limited to, 2,3 dihydrobenzofuran2yl, 2,3 dihydrobenzofuran3yl, indolin1yl, indolin2yl, indolin3yl, 2,3 dihydrobenzothien2yl, decahydroquinolinyl, decahydroisoquinolinyl, octahydro1Hindolyl, and octahydrobenzofuranyl. In embodiments, the heterocyclyl group is optionally substituted with one or two groups that are independently oxo or thia. In certain embodiments, the bicyclic heterocyclyl is a 5- or 6-membered monocyclic heterocyclyl ring fused to a phenyl ring, a 5- or 6-membered monocyclic cycloalkyl, a 5- or 6-membered monocyclic cycloalkenyl, a 5- or 6-membered monocyclic heterocyclyl, or a 5- or 6-membered monocyclic heteroaryl, and the bicyclic heterocyclyl is optionally substituted with one or two groups that are independently oxo or thia. A polycyclic heterocyclyl ring system is a monocyclic heterocyclyl ring (base ring) fused to either (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl, or (ii) two other ring systems independently selected from the group consisting of phenyl, bicyclic aryl, monocyclic or bicyclic heteroaryl, monocyclic or bicyclic cycloalkyl, monocyclic or bicyclic cycloalkenyl, and monocyclic or bicyclic heterocyclyl. The polycyclic heterocyclyl is connected to the parent molecular moiety through any carbon or nitrogen atom contained within the base ring. In embodiments, the polycyclic heterocyclyl ring system is a monocyclic heterocyclyl ring (group ring) fused to either (i) one ring system selected from the group consisting of bicyclic aryl, bicyclic heteroaryl, bicyclic cycloalkyl, bicyclic cycloalkenyl, and bicyclic heterocyclyl, or (ii) two other ring systems independently selected from the group consisting of phenyl, monocyclic heteroaryl, monocyclic cycloalkyl, monocyclic cycloalkenyl, and monocyclic heterocyclyl.Examples of polycyclic heterocyclyl groups include, but are not limited to, 10H-phenothiazin-10-yl, 9,10-dihydroacridin-9-yl, 9,10-dihydroacridin-10-yl, 10H-phenoxazin-10-yl, 10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl, 1,2,3,4-tetrahydropyrido[4,3-g]isoquinolin-2-yl, 12H-benzo[b]phenoxazin-12-yl, and dodecahydro-1H-carbazol-9-yl.

[0024] The term "alkylene," by itself or as part of another substituent, unless otherwise stated, includes, but is not limited to, -CH 2 CH 2 CH 2 CH 2 "Alkyl" refers to a divalent group derived from an alkyl, as exemplified by -. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A "lower alkyl" or "lower alkylene" is a shorter chain alkyl or alkylene group, generally having 8 or fewer carbon atoms. The term "alkenylene," by itself or as part of another substituent, means, unless otherwise stated, a divalent group derived from an alkene.

[0025] The term "heteroalkyl", by itself or in combination with another term, means, unless otherwise specified, a stable linear or branched chain, or combination thereof, containing at least one carbon atom and at least one heteroatom (e.g., O, N, S, Si, or P), where the nitrogen and sulfur atoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heteroatom(s) (e.g., O, N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is a non-cyclized chain. Examples include, but are not limited to: -CH 2 -CH 2 -O-CH3 , -CH 2 -CH 2 -NH-CH 3 , -CH 2 -CH 2 -N(CH 3 )-CH 3 , -CH 2 -S-CH 2 -CH 3 , -CH 2 -CH 2 , -S(O)-CH 3 , -CH 2 -CH 2 -S(O) 2 -CH 3 , -CH=CH-O-CH 3 , -Si(CH 3 ) 3 , -CH 2 -CH=N-OCH 3 , -CH=CH-N(CH 3 )-CH 3 , -O-CH 3 , -O-CH 2 -CH 3 Up to two or three heteroatoms may be consecutive, for example, -CH 2 -NH-OCH 3 and -CH 2 -O-Si(CH 3 ) 3and the like. The heteroalkyl moiety may contain one heteroatom (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain two optional different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain three optional different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain four optional different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain five optional different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may contain up to eight optional different heteroatoms (e.g., O, N, S, Si, or P). The term "heteroalkenyl", by itself or in combination with another term, means a heteroalkyl containing at least one double bond, unless otherwise specified. The heteroalkenyl may optionally contain, in addition to one or more double bonds, two or more double bonds and / or one or more triple bonds. The term "heteroalkynyl," by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl containing at least one triple bond. Heteroalkynyl can optionally contain, in addition to one or more triple bonds, two or more triple bonds and / or one or more double bonds.

[0026] Similarly, the term "heteroalkylene," by itself or as part of another substituent, unless otherwise stated, includes, but is not limited to, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2Heteroalkyl refers to a divalent group derived from heteroalkyl, as exemplified by -. For heteroalkylene groups, heteroatoms may occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Additionally, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O) 2 R' is -C(O) 2 R'- and -R'C(O) 2 As mentioned above, heteroalkyl groups, as used herein, include groups that are connected to the remainder of the molecule through a heteroatom, such as, for example, -C(O)R', -C(O)NR', ​​-NR'R", -OR', -SR', and / or -SO. 2 Examples of heteroalkyl groups include -R'. Where "heteroalkyl" is shown followed by a specific heteroalkyl group (e.g., -NR'R", etc.), it will be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the specific heteroalkyl group is shown to add clarity. Thus, the term "heteroalkyl" should not be construed herein to exclude specific heteroalkyl groups such as -NR'R".

[0027] The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in combination with other terms, refer to cyclic embodiments of "alkyl" and "heteroalkyl", respectively, unless otherwise specified. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A "cycloalkylene" and a "heterocycloalkylene," alone or as part of another substituent, mean a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively.

[0028] The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, "halo(C 1 -C 4 The term "alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0029] The term "acyl," unless otherwise specified, means -C(O)R, where R is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0030] The term "aryl", unless otherwise specified, means a polyunsaturated aromatic hydrocarbon substituent, which may be a single ring or multiple rings (e.g., 1-3 rings) fused together (i.e., fused-ring aryl) or covalently bonded together. Fused-ring aryl refers to multiple rings fused together, at least one of the fused rings being an aryl ring. The term "heteroaryl" refers to an aryl group (or ring) containing at least one heteroatom, such as N, O, or S, where the nitrogen and sulfur atoms are optionally oxidized and the nitrogen atom(s) are optionally quaternized. Thus, the term "heteroaryl" includes fused-ring heteroaryl groups (i.e., multiple rings fused together, where at least one of the fused rings is a heteroaromatic ring). 5,6-fused-ring heteroarylene refers to two rings fused together, where one ring has 5 members and the other ring has 6 members, and where at least one ring is a heteroaryl ring. Similarly, a 6,6-fused ring heteroarylene refers to two rings fused together, one ring having 6 members and the other ring having 6 members, and at least one ring is a heteroaryl ring. A 6,5-fused ring heteroarylene refers to two rings fused together, one ring having 6 members and the other ring having 5 members, and at least one ring is a heteroaryl ring. The heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom.Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzoxazoyl, benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl ... Examples of suitable aryl and heteroaryl ring systems include dazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An "arylene" and a "heteroarylene," alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. The heteroaryl group substituent may be -O- attached to a ring heteroatom nitrogen.

[0031] A spirocyclic ring is two or more rings in which adjacent rings are connected through a single atom. The individual rings in a spirocyclic ring may be the same or different. The individual rings in a spirocyclic ring may be substituted or unsubstituted and may have different substituents than the other individual rings in a set of spiro rings. The possible substituents for the individual rings in a spirocyclic ring are the possible substituents for the same ring when not part of a spirocyclic ring (e.g., the substituents for a cycloalkyl or heterocycloalkyl ring). A spirocyclic ring may be a substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heterocycloalkylene, and the individual rings in a spirocyclic ring group may be any of the preceding list, including those with all rings of one type (e.g., all rings are substituted heterocycloalkylene, and each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, a heterocyclic spirocyclic ring means a spirocyclic ring in which at least one ring is a heterocyclic ring and each ring can be a different ring. When referring to a spirocyclic ring system, a substituted spirocyclic ring means that at least one ring is substituted and each ring can be optionally different.

[0032] symbol [ka] indicates the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.

[0033] The term "oxo," as used herein, means an oxygen that is double bonded to a carbon atom.

[0034] The term "alkylarylene" as an arylene moiety covalently linked to an alkylene moiety (also referred to herein as an alkylene linker). In embodiments, the alkylarylene group has the formula: [ka] has.

[0035] The alkylarylene moiety may contain (e.g., in a substituent) a halogen, oxo, -N 3 , -CF 3 , -CCl 3 , -CBr 3 , -CI 3 , -CN, -CHO, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 CH 3 -SO 3 H, -OSO 3 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(O)NHNH 2 , substituted or unsubstituted C 1 -C 5 In an embodiment, the alkylarylene is unsubstituted.

[0036] Each of the above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl," "heterocycloalkyl," "aryl," and "heteroaryl") includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0037] Substituents for the alkyl and heteroalkyl groups (including groups commonly referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) include, but are not limited to, -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -CO 2R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O) 2 R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R")=NR"', -S(O)R', -S(O) 2 R', -S(O) 2 NR'R", -NRSO 2 R', -NR'NR"R"', -ONR'R", -NR'C(O)NR"NR"'R"", -CN, -NO 2 , -NR'SOR", -NR'C(O)R", -NR'C(O)-OR", -NR'OR", where m' is the total number of carbon atoms in such group. R, R', R", R"', and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When the compounds described herein include more than one R group, for example, each of the R groups is independently selected such that when two or more of these groups are present, each is an R', R", R"', and R"" group. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, the term "alkyl" is taken to include haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g., -C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 One of ordinary skill in the art will recognize that this is meant to include groups that contain carbon atoms bonded to groups other than hydrogen groups, such as aryl, aryloxy ...

[0038] Similar to the substituents described for the alkyl group, substituents for the aryl and heteroaryl groups are varied and include, for example, -OR', -NR'R", -SR', -halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -CO in numbers ranging from zero to the total number of open valences on the aromatic ring system. 2 R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O) 2 R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R")=NR"', -S(O)R', -S(O) 2 R', -S(O) 2 NR'R", -NRSO 2 R', -NR'NR"R"', -ONR'R", -NR'C(O)NR"NR"'R"", -CN, -NO 2 , -R', -N 3 , -CH(Ph) 2 , Fluoro(C 1 -C 4 )Alkoxy, Fluoro(C 1 -C 4 ) alkyl, -NR'SO 2 R", -NR'C(O)R", -NR'C(O)-OR", -NR'OR", where R', R", R'', and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When the compounds described herein include more than one R group, for example, each of the R groups is independently selected such that when two or more of these groups are present, each is an R', R", R'', and R"" group.

[0039] Substituents for a ring (e.g., cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be shown as substituents on the ring rather than on a specific atom of the ring (commonly referred to as floating substituents). In such cases, the substituents may be attached to any of the ring atoms (subject to the rules of chemical valency), and in the case of a fused or spirocyclic ring, a substituent shown as associated with one ring member of the fused or spirocyclic ring (floating substituents on a single ring) may be a substituent on any of the fused or spirocyclic rings (floating substituents on multiple rings). When a substituent is attached to a ring rather than to a specific atom (floating substituents) and the substituent subscript is an integer greater than 1, the multiple substituents may be on the same atom, on the same ring, on different atoms, on different fused rings, on different spirocyclic rings, and each substituent may optionally be different. If the point of attachment of the ring to the rest of the molecule is not limited to a single atom (floating substituent), the point of attachment may be any atom of the ring, or, in the case of a fused or spirocyclic ring, any atom of either the fused or spirocyclic ring, following the rules of chemical valency. If a ring, fused or spirocyclic ring contains one or more ring heteroatoms and the ring, fused or spirocyclic ring is shown with one or more floating substituents (including but not limited to the point of attachment to the rest of the molecule), the floating substituent may be attached to the heteroatom. If a ring heteroatom is shown attached to one or more hydrogens in a structure of a formula with floating substituents (e.g., a ring nitrogen with two bonds to a ring atom and a third bond to a hydrogen), it will be understood that when the heteroatom is attached to the floating substituent, the substituent replaces the hydrogen, following the rules of chemical valency.

[0040] Optionally, two or more substituents may be linked to form an aryl, heteroaryl, cycloalkyl, or heterocycloalkyl group. Such so-called ring-forming substituents are typically, but not necessarily, found to be attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent moieties of the base structure. For example, two ring-forming substituents attached to adjacent moieties of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single moiety of the base structure. For example, two ring-forming substituents attached to a single moiety of a cyclic base structure create a spiro ring structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent moieties of the base structure.

[0041] Two of the substituents on adjacent atoms of the aryl or heteroaryl ring are optionally represented by the formula -TC(O)-(CRR') q -U-, where T and U are independently -NR-, -O-, -CRR'-, or a single bond, and q is an integer from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -A-(CH 2 ) r A and B may be independently substituted with a substituent of -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O) 2 -, -S(O) 2 NR'-, or a single bond, where r is an integer from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a group of the formula -(CRR') s -X'-(C”R”R”') d In the formula, s and d are independently an integer of 0 to 3, and X' is -O-, -NR'-, -S-, -S(O)-, -S(O) 2 - or -S(O) 2The substituents R, R', R", and R"' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.

[0042] As used herein, the term "heteroatom" or "ring heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0043] As used herein, a "substituent" means a group selected from the following moieties: (A) Oxo, halogen, -CF 3 , -CCl 3 , -CBr 3 , -CI 3 , -CHF 2 , -CHCl 2 , -CHBr 2 , -CHI 2 , -CH 2 F, -CH 2 Cl, -CH 2 Br, -CH 2 I, -CN, -N 3 , -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(O)NHNH 2 , -NHC(O)NH 2 , -NHSO 2 H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCF 3 , -OCCl 3 , -OCBr 3 , -OCI 3 , -OCHF 2 , -OCHCl 2, -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, -OCH 2 I, unsubstituted alkyl (e.g., C 1 -C 8 Alkyl, C 1 -C 6 Alkyl or C 1 -C 4 alkyl), unsubstituted heteroalkyl (e.g., 2-8 membered heteroalkyl, 2-6 membered heteroalkyl, or 2-4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C 3 -C 8 Cycloalkyl, C 3 -C 6 Cycloalkyl, or C 5 -C 6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C 6 -C 10 Aryl, C 10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and (B) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from the following: (i) oxo, halogen, -CF 3 , -CCl 3 , -CBr 3 , -CI 3 , -CHF 2 , -CHCl 2 , -CHBr 2 , -CHI 2 , -CH 2 F, -CH 2 Cl, -CH 2 Br, -CH 2 I, -CN, -N 3 , -OH, -NH2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(O)NHNH 2 , -NHC(O)NH 2 , -NHSO 2 H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCF 3 , -OCCl 3 , -OCBr 3 , -OCI 3 , -OCHF 2 , -OCHCl 2 , -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, -OCH 2 I, unsubstituted alkyl (e.g., C 1 -C 8 Alkyl, C 1 -C 6 Alkyl or C 1 -C 4 alkyl), unsubstituted heteroalkyl (e.g., 2-8 membered heteroalkyl, 2-6 membered heteroalkyl, or 2-4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C 3 -C 8 Cycloalkyl, C 3 -C 6 Cycloalkyl, or C 5 -C 6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C 6 -C 10 Aryl, C 10aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and (ii) alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from the following: (a) Oxo, halogen, -CF 3 , -CCl 3 , -CBr 3 , -CI 3 , -CHF 2 , -CHCl 2 , -CHBr 2 , -CHI 2 , -CH 2 F, -CH 2 Cl, -CH 2 Br, -CH 2 I, -CN, -N 3 , -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(O)NHNH 2 , -NHC(O)NH 2 , -NHSO 2 H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCF 3 , -OCCl 3 , -OCBr 3 , -OCI 3 , -OCHF 2 , -OCHCl 2 , -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, -OCH 2 I, unsubstituted alkyl (e.g., C 1 -C 8 Alkyl, C1 -C 6 Alkyl or C 1 -C 4 alkyl), unsubstituted heteroalkyl (e.g., 2-8 membered heteroalkyl, 2-6 membered heteroalkyl, or 2-4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C 3 -C 8 Cycloalkyl, C 3 -C 6 Cycloalkyl, or C 5 -C 6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C 6 -C 10 Aryl, C 10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and (b) Oxo, halogen, -CF 3 , -CCl 3 , -CBr 3 , -CI 3 , -CHF 2 , -CHCl 2 , -CHBr 2 , -CHI 2 , -CH 2 F, -CH 2 Cl, -CH 2 Br, -CH 2 I, -CN, -N 3 , -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SCH 3 , -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 , -NHC(O)NHNH 2 , -NHC(O)NH 2 , -NHSO 2H, -NHC(O)H, -NHC(O)OH, -NHOH, -OCF 3 , -OCCl 3 , -OCBr 3 , -OCI 3 , -OCHF 2 , -OCHCl 2 , -OCHBr 2 , -OCHI 2 , -OCH 2 F, -OCH 2 Cl, -OCH 2 Br, -OCH 2 I, unsubstituted alkyl (e.g., C 1 -C 8 Alkyl, C 1 -C 6 Alkyl or C 1 -C 4 alkyl), unsubstituted heteroalkyl (e.g., 2-8 membered heteroalkyl, 2-6 membered heteroalkyl, or 2-4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C 3 -C 8 Cycloalkyl, C 3 -C 6 Cycloalkyl, or C 5 -C 6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C 6 -C 10 Aryl, C 10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl).

[0044] "Size-limited substituent" or "size-limited substituent group" as used herein means a group selected from all of the substituents listed above for "substituent", where each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 20 each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 20-membered heteroalkyl; and each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 8 each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3- to 8-membered heterocycloalkyl; each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 10-membered heteroaryl.

[0045] "Lower substituent" or "lower substituent group" as used herein means a group selected from all of the substituents listed above for "substituent", where each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 8 each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2-8 membered heteroalkyl; and each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3- to 7-membered heterocycloalkyl; each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 9-membered heteroaryl.

[0046] In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, and / or unsubstituted heteroarylene, respectively). In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is substituted (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene, respectively).

[0047] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent, and when a substituted moiety is substituted with multiple substituents, each substituent may optionally be different. In embodiments, when a substituted moiety is substituted with multiple substituents, each substituent is different.

[0048] In embodiments, a substituted moiety (e.g., a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one size-limited substituent, and when a substituted moiety is substituted with multiple size-limited substituents, each size-limited substituent may optionally be different. In embodiments, when a substituted moiety is substituted with multiple size-limited substituents, each size-limited substituent is different.

[0049] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one lower substituent, and when a substituted moiety is substituted with multiple lower substituents, each lower substituent may optionally be different. In embodiments, when a substituted moiety is substituted with multiple lower substituents, each lower substituent is different.

[0050] In embodiments, a substituted moiety (e.g., a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent, size-limited substituent, or lower substituent, and when a substituted moiety is substituted with multiple substituents selected from substituents, size-limited substituents, and lower substituents, each substituent, size-limited substituent, and / or lower substituent may optionally be different. In embodiments, when a substituted moiety is substituted with multiple substituents selected from substituents, size-limited substituents, and lower substituents, each substituent, size-limited substituent, and / or lower substituent is different.

[0051] In embodiments of the compounds herein, each substituted or unsubstituted alkyl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 1 -C 20 each substituted or unsubstituted heteroalkyl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 2-20 membered heteroalkyl; each substituted or unsubstituted cycloalkyl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 3 -C 8 each substituted or unsubstituted heterocycloalkyl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 3-8 membered heterocycloalkyl; each substituted or unsubstituted aryl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 6 -C 10aryl, and / or each substituted or unsubstituted heteroaryl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 5-10 membered heteroaryl. In embodiments herein, each substituted or unsubstituted alkylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 1 -C 20 each substituted or unsubstituted heteroalkylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 2-20 membered heteroalkylene; each substituted or unsubstituted cycloalkylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 3 -C 8 each substituted or unsubstituted heterocycloalkylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 3-8 membered heterocycloalkylene; each substituted or unsubstituted arylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 6 -C 10 arylene, and / or each substituted or unsubstituted heteroarylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 5-10 membered heteroarylene.

[0052] In embodiments, each substituted or unsubstituted alkyl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 1 -C 8 each substituted or unsubstituted heteroalkyl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 2-8 membered heteroalkyl; each substituted or unsubstituted cycloalkyl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C3 -C 7 each substituted or unsubstituted heterocycloalkyl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 3-7 membered heterocycloalkyl; each substituted or unsubstituted aryl is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 6 -C 10 In embodiments, each substituted or unsubstituted alkylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 5-9 membered heteroaryl. 1 -C 8 each substituted or unsubstituted heteroalkylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted 2-8 membered heteroalkylene; each substituted or unsubstituted cycloalkylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 3 -C 7 each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3- to 7-membered heterocycloalkylene; each substituted or unsubstituted arylene is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted C 6 -C 10 and / or each substituted or unsubstituted heteroarylene is a substituted (e.g., substituted, size-limited, or lower substituent) or unsubstituted 5-9 membered heteroarylene. In embodiments, the compound is a species described in the Examples section, Figures, or Tables below.

[0053] Certain compounds provided herein have asymmetric carbon atoms (optical or chiral centers) or double bonds, and enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms, and individual isomers that may be defined as (R)- or (S)- or (D)- or (L) for amino acids in terms of absolute stereochemistry are encompassed within the scope of the present disclosure. Compounds provided herein do not include those known in the art to be too unstable to synthesize and / or isolate. Compounds provided herein include compounds in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When a compound described herein contains an olefinic bond or other geometrically asymmetric center, it is intended that the compound include both E and Z geometric isomers, unless otherwise specified.

[0054] As used herein, the term "isomers" refers to compounds having the same number and kinds of atoms, and therefore the same molecular weight, but differing with respect to the structural arrangement or configuration of the atoms.

[0055] The term "tautomer," as used herein, refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another.

[0056] It will be apparent to one of ordinary skill in the art that certain compounds provided herein may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure.

[0057] When the compounds disclosed herein have at least one chiral center, they can exist as individual enantiomers and diastereomers, or as mixtures of such isomers, including racemates. Separation of individual isomers or selective synthesis of individual isomers can be achieved by application of various methods well known to practitioners in the art. Unless otherwise indicated, all such isomers and their mixtures are included within the scope of the compounds disclosed herein. Unless otherwise indicated, the structures shown herein are also intended to include all stereochemical forms of the structures, i.e., the (R) and (S) configurations of each asymmetric center. Thus, single stereochemical isomers, as well as enantiomeric and diastereomeric mixtures of the compounds, that are generally recognized by those skilled in the art as stable, are within the scope of the present disclosure.

[0058] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, the replacement of hydrogen by deuterium or tritium; 18 Replacement of fluoride by F, or 13 C or 14 Compounds having this structure, except for the replacement of a carbon with a C-enriched carbon, are within the scope of this disclosure.

[0059] The compounds provided herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may contain, for example, tritium ( 3 H), iodine-125( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds provided herein, whether radioactive or not, are included within the disclosure.

[0060] It should be noted that throughout this application, alternatives are described in Markush groups, e.g., at each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of a Markush group should be considered separately, thereby including alternative embodiments, and that the Markush group should not be read as a single unit.

[0061] "Analog" or "analogue" is used according to its obvious common meaning in chemistry and biology to refer to a chemical compound that is structurally similar to another compound (i.e., a so-called "reference compound") but differs in composition, for example, in the replacement of one atom with an atom of a different element, or in the presence of a particular functional group, or in the replacement of one functional group with another, or in the absolute stereochemistry of one or more chiral centers of the reference compound. Thus, an analog is a compound that is similar or equivalent in function and appearance, but not similar or equivalent in structure or origin to the reference compound.

[0062] The terms "a" or "an" as used herein means one or more. Additionally, the phrase "substituted with a[n]" as used herein means that the particular group may be substituted with one or more of any or all of the specified substituents. For example, a group, e.g., an alkyl or heteroaryl group, may be substituted with "one unsubstituted C 1 -C 20 When "substituted with alkyl, or unsubstituted 2-20 membered heteroalkyl," the group is selected from the group consisting of one or more unsubstituted C 1 -C 20 It may contain one or more unsubstituted 2-20 membered alkyl, and / or one or more unsubstituted 2-20 membered heteroalkyl.

[0063] When a moiety is substituted with an R substituent, the group may be referred to as "R-substituted." When a moiety is R-substituted, the moiety is substituted with at least one R substituent, and each R substituent is optionally different. When a particular R group is present in a description of a chemical genus (such as formula (I)), the Roman numeral decimal symbol may be used to distinguish between each occurrence of that particular R group. For example, multiple R 13 When substituents are present, each R 13 The substituent is R 13.1 , R 13.2 , R 13.3 , R 13.4 etc., R 13.1 , R 13.2 , R 13.3 , R 13.4 etc. are R 13 The terms "a" or "an" as used herein mean one or more. Additionally, the phrase "substituted with a[n]" as used herein means that the particular group may be substituted with one or more of any or all of the specified substituents. For example, a group, e.g., an alkyl or heteroaryl group, may be substituted with "one (an) unsubstituted C 1 -C 20 When "substituted with alkyl, or unsubstituted 2-20 membered heteroalkyl," the group is selected from the group consisting of one or more unsubstituted C 1 -C 20 It may contain one or more unsubstituted 2-20 membered alkyl, and / or one or more unsubstituted 2-20 membered heteroalkyl.

[0064] The description of compounds provided herein is limited by the principles of chemical bonding known to those skilled in the art.Therefore, when a group can be substituted by one or more of several substituents, such substituents are selected to provide a compound that is not inherently unstable and / or would be known to those skilled in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and some known physiological conditions.For example, heterocycloalkyl or heteroaryl is connected to the rest of the molecule through ring heteroatoms, according to the principles of chemical bonding known to those skilled in the art, thereby avoiding inherently unstable compounds.

[0065] The term "pharmaceutically acceptable salts" refers to salts that retain the biological effectiveness and properties of a compound and that are not undesirable for biological or other pharmaceutical use. In many cases, the compounds herein are capable of forming acid and / or base salts due to the presence of amino and / or carboxyl groups, or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, etc., and particularly preferably ammonium, potassium, sodium, calcium, and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, etc., specifically, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many of these salts are known in the art, as described in WO87 / 05297, published September 11, 1987, Johnston et al., which is incorporated herein by reference in its entirety.

[0066] "Contacting" is used according to its plain and ordinary meaning to refer to a process that allows at least two different species (e.g., chemical compounds, biomolecules, or cells) to come into sufficient proximity to react, interact, or come into physical contact. For example, contacting includes a process that allows a compound to come into sufficient proximity with a cell to bind to a cell surface receptor.

[0067] As used herein, "contacting a cell" refers to a condition in which a compound or other composition of matter is in direct contact with a cell or in sufficient proximity to induce a desired biological effect in the cell.

[0068] The term "free uptake conditions" as used herein refers to conditions in which unmodified oligonucleotides do not substantially enter cells. For example, such free uptake conditions can be conditions in which there is little or no transfection reagents, electroporation techniques, or other conditions used to promote entry of compounds into cells. Free uptake conditions can also be conditions in which siRNA lacking lipid conjugation does not substantially enter cells, such as incubation in standard medium under standard conditions for a particular type of cell. An example of a standard medium condition for free uptake can be fetal bovine serum (FBS) in the range of 0.5% to 10%, for example 1% to 5%. In other examples, the standard medium is serum-free.

[0069] The term "activator" refers to a compound, composition, or substance that can detectably increase the expression or activity of a given gene or protein. For example, an activator can increase expression or activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more compared to a control in the absence of the activator.

[0070] As defined herein, terms such as "inhibit", "inhibit", "inhibiting" and the like refer to adversely affecting (e.g., decreasing) an activity or function compared to the activity or function in the absence of the inhibitor. In embodiments, inhibition refers to adversely affecting (e.g., decreasing) the concentration or level of a biomolecule, such as a protein or mRNA, compared to the concentration or level of the biomolecule in the absence of the inhibitor. For example, inhibition includes decreasing the level of mRNA expression in a cell. In embodiments, inhibition refers to a decrease in the activity of a particular biomolecular target, such as a protein target or an mRNA target. Thus, inhibition includes at least partially, partially or completely blocking a stimulus, decreasing, preventing or delaying activation, or inactivating, desensitizing or downregulating a signaling or enzymatic activity or the amount of a biomolecule. In embodiments, inhibition refers to a decrease in the activity of a target biomolecule resulting from a direct interaction (e.g., an inhibitor binds to a target protein). In embodiments, inhibition refers to a decrease in the activity of a target biomolecule from an indirect interaction (e.g., an inhibitor binds to a protein that activates the target protein, thereby preventing activation of the target protein).

[0071] The term "inhibitor" also refers to a compound, composition, or substance that can detectably reduce the expression or activity of a given gene or protein. For example, an inhibitor can reduce expression or activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more compared to a control in the absence of the inhibitor. Inhibitors include, for example, biological molecules such as synthetic molecules or oligonucleotides.

[0072] As used herein, the terms "expression" and "gene expression" refer to the step involved in the translation of nucleic acid into protein, including mRNA expression and protein expression. Expression can be detected using conventional techniques for detecting nucleic acid or protein (e.g., PCR, ELISA, Southern blot, Southern blotting, Western blotting, flow cytometry, FISH, immunofluorescence, immunohistochemistry).

[0073] An "effective amount" is an amount sufficient for a compound to achieve a stated purpose (e.g., achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signal transduction pathway, or alleviate one or more symptoms of a disease or condition) compared to the absence of the compound. An "activity-reducing amount," as used herein, refers to the amount of antagonist required to reduce the activity of an enzyme compared to the absence of the antagonist. A "function-disrupting amount," as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein compared to the absence of the antagonist.

[0074] The term "cell" is used herein in its ordinary sense as understood by those of skill in the art. A cell may be prokaryotic or eukaryotic. Prokaryotic cells include, but are not limited to, bacteria. Eukaryotic cells include, but are not limited to, yeast cells, plant cells, and animal cells, including human cells. Cells can be identified by methods well known in the art, including, for example, the presence of an intact membrane, staining with a particular dye, the ability to produce progeny, or, in the case of gametes, the ability to combine with a second gamete to produce viable progeny. In embodiments, the cell may be from an immortalized cell line. In embodiments, the cell may be a primary cell. In embodiments, the cell is in vitro. In embodiments, the cell is in vivo. In embodiments, the cell is ex vivo.

[0075] As used herein, the term "in vivo" refers to a process that takes place within a subject's body.

[0076] As used herein, the term "subject" means a human or non-human animal selected for treatment or therapy. In embodiments, the subject is a human.

[0077] The term "ex vivo" as used herein refers to a process carried out in vitro on isolated tissues or cells, where the treated tissues or cells include primary cells. As is known in the art, any medium used in this process can be aqueous and non-toxic so as not to render the tissues or cells non-viable. In an embodiment, the ex vivo process is carried out in vitro using primary cells.

[0078] The term "administration" means providing an agent or composition to a subject, and includes administration by a medical professional and self-administration.

[0079] The term "therapy" refers to the application of one or more specific procedures used to improve at least one indication or disease or condition. In embodiments, the specific procedure is the administration of one or more drugs.

[0080] The term "modulate" is used herein in its ordinary sense as understood by those skilled in the art, and thus refers to the act of changing or altering one or more characteristics. For example, in terms of the effect of a regulator on a target molecule, modulating the characteristics or function of the target molecule, or a means for changing the amount of the target molecule by increasing or decreasing it. A regulator of a disease reduces the symptoms, causes, or characteristics of the target disease.

[0081] The terms "nucleic acid", "oligonucleotide", and "polynucleotide" refer to a compound containing at least two nucleotide monomers covalently linked together. The terms include single-stranded and double-stranded nucleic acids, nucleic acids, oligonucleotides, and polynucleotides, including single-stranded DNA, double-stranded DNA, single-stranded RNA, double-stranded RNA, single-stranded and double-stranded molecules containing both DNA and RNA nucleotides, and modified versions thereof. Oligonucleotides refer to shorter length polymers, typically about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50, or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are typically longer length nucleotide polymers, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000 nucleotides. A "residue" of a nucleic acid, oligonucleotide, or polynucleotide refers to a nucleotide monomer of the compound. "Residue" and "monomer" are used interchangeably herein. In an embodiment, the oligonucleotide may be used for RNA silencing. In an embodiment, the oligonucleotide may comprise DNA, locked nucleic acid (LNA), bicyclic nucleic acid (BNA), or phosphorodiamidate morpholino oligomer (PMO), or modifications thereof, etc. In an embodiment, the oligonucleotide comprises one or more 2'-O-methoxyethyl residues, 2'-O-methyl residues, and / or 2'-fluoro residues. In an embodiment, the oligonucleotide comprises phosphorothioate linkages.

[0082] Non-limiting examples of oligonucleotides include double-stranded oligonucleotides, modified double-stranded oligonucleotides, single-stranded oligonucleotides, modified single-stranded oligonucleotides, antisense oligonucleotides, siRNAs, microRNA mimics, stem-loop structures, single-stranded siRNAs, RNase H oligonucleotides, anti-microRNA oligonucleotides, sterically hindered oligonucleotides, CRISPR guide RNAs, and aptamers.

[0083] Non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, intergenic DNA (including but not limited to heterochromatic DNA), messenger RNA (mRNA), long non-coding RNA, transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of sequences, and isolated RNA of sequences.Polynucleotides useful in the methods of the present disclosure may include naturally occurring nucleic acid sequences and variants thereof, artificial nucleic acid sequences, or combinations of such sequences.

[0084] "Nucleoside," as used herein, refers to a glycosyl compound consisting of a nucleobase and a five-membered ring sugar (e.g., either ribose or deoxyribose). A nucleoside may include a base such as A, C, G, T, U, or analogs thereof. A nucleoside may be modified in the base and / or sugar. In one embodiment, a nucleoside is a deoxyribonucleoside. In another embodiment, a nucleoside is a ribonucleoside.

[0085] "Nucleotide" as used herein refers to a nucleoside-5'-polyphosphate compound, or structural analog thereof, which may be incorporated by a nucleic acid polymerase (e.g., partially incorporated as a nucleoside-5'-monophosphate or derivative thereof) to extend a growing nucleic acid chain (e.g., a primer). A nucleotide may contain a base such as A, C, G, T, U, or analogs thereof, and may contain 2, 3, 4, 5, 6, 7, 8, or more phosphates in the phosphate group. A nucleotide may be modified at one or more of the base, sugar, or phosphate group. A nucleotide may have a ligand attached directly or via a linker. In one embodiment, a nucleotide is a deoxyribonucleotide. In another embodiment, a nucleotide is a ribonucleotide.

[0086] As used herein, "nucleotide analog" shall mean an analog of A, G, C, T, or U (i.e., an analog of a nucleotide containing the bases A, G, C, T, or U) that contains a phosphate group that can be recognized by a DNA or RNA polymerase (as applicable) and incorporated into a DNA or RNA strand (as applicable). Examples of nucleotide analogs include, but are not limited to, 7-deaza-adenine, 7-deaza-guanine, analogs of deoxynucleotides as set forth herein, analogs in which a label is attached to the 5-position of cytosine or thymine or the 7-position of deaza-adenine or deaza-guanine through a cleavable linker, and analogs in which a small chemical moiety is used to protect the OH group at the 3' position of deoxyribose. Nucleotide analogs and DNA polymerase-based DNA sequencing are also described in U.S. Patent No. 6,664,079, which is incorporated herein by reference in its entirety for all purposes.

[0087] The term "base" in the context of an oligonucleotide, nucleic acid or polynucleotide, and "nucleobase" as used herein, refers to a purine or pyrimidine compound or derivative thereof that may be a component of a nucleic acid (i.e., DNA or RNA, or a derivative thereof). In an embodiment, the nucleobase is a derivative of a naturally occurring DNA or RNA base (e.g., a base analog). In an embodiment, the nucleobase is a derivative of a naturally occurring DNA or RNA base (e.g., a base analog), which may be optionally substituted. In an embodiment, the nucleobase is a hybridization base. In an embodiment, the nucleobase is a hybridization base, which may be optionally substituted. In an embodiment, the nucleobase hybridizes to a complementary base. In an embodiment, the nucleobase is capable of forming at least one hydrogen bond with a complementary nucleobase (e.g., an adenine hydrogen bond with thymine, an adenine hydrogen bond with uracil, or a guanine pair with cytosine). Non-limiting examples of nucleobases include cytosine or a derivative thereof (e.g., a cytosine analog), guanine or a derivative thereof (e.g., a guanine analog), adenine or a derivative thereof (e.g., an adenine analog), thymine or a derivative thereof (e.g., a thymine analog), uracil or a derivative thereof (e.g., a uracil analog), hypoxanthine or a derivative thereof (e.g., a hypoxanthine analog), xanthine or a derivative thereof (e.g., a xanthine analog), 7-methylguanine or a derivative thereof (e.g., a 7-methylguanine analog), Examples of the nucleic acid base include a deaza-adenine or derivative thereof (e.g., a deaza-adenine analog), a deaza-guanine or derivative thereof (e.g., a deaza-guanine), a deaza-hypoxanthine or derivative thereof, a 5,6-dihydrouracil or derivative thereof (e.g., a 5,6-dihydrouracil analog), a 5-methylcytosine or derivative thereof (e.g., a 5-methylcytosine analog), or a 5-hydroxymethylcytosine or derivative thereof (e.g., a 5-hydroxymethylcytosine analog) moiety. In embodiments, the nucleobase is an adenine, guanine, hypoxanthine, xanthine, theobromine, caffeine, uric acid, or isoguanine, which may be optionally substituted or modified.In embodiments, the nucleobase is: [ka] and may be optionally substituted or modified.

[0088] Oligonucleotides, nucleic acids, and polynucleotides may contain non-specific sequences. As used herein, the term "non-specific sequence" refers to a sequence that contains a series of residues that are not designed to be complementary or only partially complementary to any other sequence. As an example, the two strands of a double-stranded oligonucleotide may be hybridized in a manner that results in one or more short (e.g., two) nucleotide overhangs at one or both ends of the double strand. As another example, a non-specific nucleic acid sequence is a sequence of nucleic acid residues that does not function as an inhibitory nucleic acid when contacted with a cell or organism.

[0089] The term "double-stranded oligonucleotide" as used herein refers to an oligonucleotide having a nucleobase sequence that is sufficiently complementary to form a double-stranded structure. A double-stranded oligonucleotide may include a structure formed from annealing a first oligonucleotide to a second complementary oligonucleotide. A double-stranded oligonucleotide may be fully complementary over the length of both oligonucleotides. Alternatively, a double-stranded oligonucleotide may have short nucleotide overhangs at one or both ends of the double-stranded structure. Such double-stranded oligonucleotides include siRNAs and microRNA mimics. A double-stranded oligonucleotide may also include a single oligonucleotide that has sufficient length and self-complementarity to form a double-stranded structure. Such double-stranded oligonucleotides include stem-loop structures. A double-stranded oligonucleotide may include one or more modifications to the naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages.

[0090] The term "modified double-stranded oligonucleotide" as used herein refers to a double-stranded oligonucleotide that contains one or more modifications to naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages.In the case of a double-stranded oligonucleotide that contains two separate complementary oligonucleotides, one or both strands may contain one or more modifications to naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages.

[0091] The terms "small interfering RNA", "short interfering RNA", "silencing RNA" and "siRNA" are used interchangeably herein to refer to a group of double-stranded oligonucleotides that disrupt the expression of specific genes by promoting the degradation of mRNA before translation (i.e., via the RNA interference pathway). siRNAs include a guide strand that is complementary to the target mRNA and is incorporated into the RNA-induced silencing complex (RISC) and a passenger strand that is complementary to the guide strand and is typically degraded. Typically, siRNA molecules are about 15-50 nucleotides in length, more typically 20-30 base nucleotides in length, 20-25 nucleotides in length, or 24-29 nucleotides in length. In embodiments, siRNAs are about 18-25 nucleotides in length. siRNAs may contain one or more modifications to the naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages.

[0092] The term "microRNA mimic" as used herein refers to a synthetic embodiment of a naturally occurring microRNA. A microRNA mimic includes a guide strand that is complementary to one or more target mRNAs and a passenger strand that is complementary to the guide strand. In a naturally occurring microRNA, the guide strand is typically only partially complementary to its target mRNA(s) and the passenger strand is only partially complementary to the guide strand. A microRNA mimic may include a nucleobase sequence that has 100% identity to a naturally occurring microRNA, or may include a nucleobase sequence that has less than 100% identity to a naturally occurring microRNA. For example, a microRNA mimic may include a passenger strand that is 100% complementary to a guide strand. A microRNA mimic may include one or more modifications to naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages.

[0093] The term "single-stranded oligonucleotide" as used herein refers to an oligonucleotide that is not hybridized to a complementary strand. Single-stranded oligonucleotides may contain one or more modifications to naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages. Single-stranded oligonucleotides include antisense oligonucleotides. Single-stranded oligonucleotides also include aptamers, which are single-stranded oligonucleotides that fold into well-defined secondary structures.

[0094] The term "modified single-stranded oligonucleotide" as used herein refers to the single-stranded oligonucleotide that is not hybridized with complementary strand and contains one or more modifications to naturally occurring termini, sugars, nucleobases, and / or internucleoside bonds.Modified single-stranded oligonucleotides include modified antisense oligonucleotides and aptamers.

[0095] An "antisense oligonucleotide" as referred to herein is a single-stranded oligonucleotide that is complementary to at least a portion of a particular target nucleic acid and thus can selectively hybridize to a particular target nucleic acid, and further can reduce transcription of the target nucleic acid (e.g., mRNA derived from DNA), reduce translation of the target nucleic acid (e.g., mRNA), alter transcript splicing, or otherwise interfere with the endogenous activity of the target nucleic acid. Typically, antisense oligonucleotides are 15-25 bases in length. Antisense oligonucleotides may contain one or more modifications to the naturally occurring termini, sugars, nucleobases, and / or internucleoside linkages. Antisense oligonucleotides include, but are not limited to, anti-microRNA oligonucleotides (oligonucleotides complementary to microRNAs), steric hinderance oligonucleotides (oligonucleotides that interfere with the activity of a target RNA without degrading the target RNA), and RNaseH oligonucleotides (oligonucleotides chemically modified to induce RNaseH-mediated degradation of a target RNA).

[0096] A nucleic acid, oligonucleotide, or polynucleotide is "modified" when one or more of its termini, phosphodiester bonds, sugars, or bases are modified from their natural form (e.g., modified from the common form in DNA or RNA to form nucleotide analogs). For example, a nucleic acid is modified when one or more of its phosphodiester bonds are replaced by phosphoramidate, phosphorothioate, phosphorodithioate, boranophosphonate, or O-methyl phosphoramidite bonds (e.g., Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press). Modified nucleic acids, oligonucleotides, and polynucleotides include those with cationic backbones, nonionic backbones, and non-ribose backbones, such as those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, Carbohydrate Modifications in Antisense Research, edited by Sanghui&Cook. Modified nucleic acids, oligonucleotides, and polynucleotides also include nucleic acids, oligonucleotides, and polynucleotides in which one or more of the residues contain a chemically altered ribose sugar, such as 2'-O-methylribose, 2'-deoxy-2'-fluoro-ribose, and ribose "locked" by a covalent bond between the 2' and 4' carbons. "Bicyclic nucleic acid" or "BNA" residues contain a covalent bond between the 2' hydroxyl groups of the sugars that connect to the 4' carbon of the sugar ring that essentially "locks" the structure into a rigid structure. A methyleneoxy (4'-CH 2 A bicyclic nucleic acid residue containing a 4'-CH(CH 3Bicyclic nucleic acid residues containing a )-O-2' bridge are "constrained ethyl" or "cEt" residues. "Unlocked nucleic acid" or "UNA" residues are acyclic nucleoside derivatives lacking a bond between the 2' and 3' carbons of the sugar ring. In addition, modified nucleic acids, oligonucleotides, and polynucleotides may be modified at one or both of the 5' and 3' termini. For example, oligonucleotides may contain 5'-(E)-vinylphosphonate groups at the termini. Nucleic acid modifications may be made for a variety of reasons, such as to increase the stability and half-life of such molecules in physiological environments or to prevent immune stimulation.

[0097] In embodiments, the oligonucleotide may consist of, consist essentially of, or comprise a single strand of a locked nucleic acid (LNA), or a modification thereof. In embodiments, the oligonucleotide may consist of, consist essentially of, or comprise a single strand of a phosphorodiamidate morpholino oligomer (PMO), or a modification thereof. In embodiments, the oligonucleotide may consist of, consist essentially of, or comprise a single strand of a phosphorodiamidate morpholino oligomer (PMO), or a modification thereof. In embodiments, the oligonucleotide may consist of at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84% of DNA, siRNA, mRNA, locked nucleic acid (LNA), bicyclic nucleic acid (BNA), or phosphorodiamidate morpholino oligomer (PMO), or a modification thereof, etc. , 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or the oligonucleotide may comprise an amount of DNA, siRNA, mRNA, locked nucleic acid (LNA), bicyclic nucleic acid (BNA), or phosphorodiamidate morpholino oligomer (PMO), or modifications thereof, within a range defined by any two of the foregoing values. In embodiments, the oligonucleotide may comprise at least 1% and less than 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, or 4% of 2'-O-methoxyethyl / phosphorothioate (MOE).

[0098] The term "complement" as used herein refers to a nucleotide (e.g., RNA or DNA) or nucleotide sequence that can base-pair with a complementary nucleotide or nucleotide sequence. As described herein and generally known in the art, the complementary (matching) nucleotide of adenosine is thymidine, and the complementary (matching) nucleotide of guanosine is cytosine. Thus, a complement may comprise a sequence of nucleotides that base-pair with the corresponding complementary nucleotide of a second nucleic acid sequence. The nucleotides of the complement may be partially or completely matched with the nucleotides of the second nucleic acid sequence. When the nucleotides of the complement completely match with each nucleotide of the second nucleic acid sequence, the complement will base-pair with each nucleotide of the second nucleic acid sequence. When the nucleotides of the complement partially match with the nucleotides of the second nucleic acid sequence, only a portion of the nucleotides of the complement will base-pair with the nucleotides of the second nucleic acid sequence. Examples of complementary sequences include coding and non-coding sequences, where the non-coding sequence contains nucleotides that are complementary to the coding sequence, thus forming the complement of the coding sequence. Further examples of complementary sequences are sense and antisense sequences, where the sense sequence contains nucleotides that are complementary to the antisense sequence, thus forming the complement of the antisense sequence.

[0099] As described herein, the complementarity of sequences may be partial, and only some of the nucleic acids are matched according to base pairing, or may be complete, and all nucleic acids are matched according to base pairing.Therefore, two sequences that are complementary to each other may have a certain percentage of nucleotides involved in nucleic acid base pairing (i.e., about 60% complementarity over a certain region, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher complementarity).

[0100] "Hybridize" shall mean annealing one single-stranded nucleic acid (such as a primer) to another nucleic acid based on the well-understood principle of sequence complementarity. In one embodiment, the other nucleic acid is a single-stranded nucleic acid. The tendency for hybridization between nucleic acids depends on the temperature and ionic strength of their environment, the length of the nucleic acid, and the degree of complementarity. The effect of these parameters on hybridization is described, for example, in Sambrook J, Fritsch EF, Maniatis T., Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, New York (1989). As used herein, the hybridization of a primer, or a DNA extension product, respectively, is extendible by the creation of a phosphodiester bond with an available nucleotide or nucleotide analog that can form a phosphodiester bond with them.

[0101] A particular nucleic acid sequence also encompasses "splice variants." Similarly, a particular protein encoded by a nucleic acid encompasses any protein encoded by a splice variant of that nucleic acid. A "splice variant" is a product of alternative splicing of a gene. After transcription, an initial nucleic acid transcript may be spliced ​​such that different (alternative) nucleic acid splice products encode different polypeptides. Mechanisms for the production of splice variants vary, but include alternative splicing of exons. Alternative polypeptides derived from the same nucleic acid by read-through transcription are also encompassed by this definition. Any product of a splicing reaction, including recombinant forms of the splice product, is included in this definition. Examples of potassium channel splice variants are described in Leicher, et al., J. Biol. Chem. 273(52):35095-35101 (1998).

[0102] The term "identical" or percentage of "identity" refers to a specified percentage of amino acid residues or nucleotides that are the same or identical (i.e., at least 60% identity, or at least 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 102%, 109%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 109%, 109%, 109%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, %, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or within a range defined by any two of the foregoing values). This definition also refers to or can be applied to the complement of a test sequence. This definition also includes sequences with deletions and / or additions, as well as sequences with substitutions. As explained below, the preferred algorithm can account for gaps, insertions, etc. Alignment for the purpose of determining sequence identity percentage can be achieved in various ways within the scope of those skilled in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithm required to achieve maximum alignment over the entire length of the sequences being compared, can be determined by known methods.

[0103] For sequence comparison, typically, one sequence serves as the reference sequence with which test sequence is compared.When using sequence comparison algorithm, test sequence and reference sequence are input into computer, subsequence coordinates are designated as necessary, and sequence algorithm program parameters are designated.Preferably, default program parameters can be used.Then, sequence comparison algorithm calculates the sequence identity percentage of test sequence to reference sequence based on program parameters.

[0104] A "comparison window," as used herein, includes reference to any one segment of a number of contiguous positions selected from the group consisting of 10 to 600, usually about 50 to about 200, more usually about 100 to about 150, where a sequence can be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods for aligning sequences for comparison are well known in the art. Optimal alignment of sequences for comparison may be performed, for example, by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l Acad. Sci. USA 85:2444 (1988), by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA by the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, for example, Current Protocols in Molecular Biology (Ausubel et al., eds., 1995 Supplement)).

[0105] Compounds and Methods In one embodiment, specifically, a compound or lipid-modified oligonucleotide compound has the structure: [ka]

[0106] A is an oligonucleotide, a nucleic acid, a polynucleotide, a nucleotide or analog thereof, or a nucleoside or analog thereof. In an embodiment, A is an oligonucleotide. In an embodiment, A is a nucleic acid. In an embodiment, A is a polynucleotide. In an embodiment, A is a nucleotide or analog thereof. In an embodiment, A is a nucleoside or analog thereof.

[0107] L 3 and L 4 each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0108] L 5 -L 5A -L 5B -L 5C -L 5D -L 5E - and L 6 -L 6A -L 6B -L 6C -L 6D -L 6E -It is. 5A , L 5B , L 5C , L 5D , L 5E , L 6A , L 6B , L 6C , L 6D , and L 6Eare independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

[0109] R 1 and R 2 are independently unsubstituted C 1 -C 25 alkyl, where R 1 and R 2 At least one of the groups is unsubstituted C 9 -C 19 In embodiments, R 1 and R 2 are independently unsubstituted C 1 -C 20 alkyl, where R 1 and R 2 At least one of the groups is unsubstituted C 9 -C 19 It is an alkyl.

[0110] R 3 is hydrogen, -NH 2 , -OH, -SH, -C(O)H, -C(O)NH 2 , -NHC(O)H, -NHC(O)OH, -NHC(O)NH 2 , -C(O)OH, -OC(O)H, -N 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0111] t is an integer from 1 to 5.

[0112] In embodiments, t is 1. In embodiments, t is 2. In embodiments, t is 3. In embodiments, t is 4. In embodiments, t is 5.

[0113] In an embodiment, A is a double-stranded oligonucleotide or a single-stranded oligonucleotide. In an embodiment, A is a double-stranded oligonucleotide. In an embodiment, A is a single-stranded oligonucleotide. In an embodiment, A is a modified oligonucleotide. In an embodiment, A is a modified double-stranded oligonucleotide, a modified single-stranded oligonucleotide. In an embodiment, A is a modified double-stranded oligonucleotide. In an embodiment, A is a modified single-stranded oligonucleotide.

[0114] In embodiments, A is an siRNA, a microRNA mimic, a stem-loop structure, a single stranded siRNA, an RNaseH oligonucleotide, an anti-microRNA oligonucleotide, a sterically hindered oligonucleotide, a CRISPR guide RNA, or an aptamer.

[0115] In an embodiment, one L 3 is attached to the 3' carbon of the double-stranded or single-stranded oligonucleotide. 3 is attached to the 3' carbon of the double stranded oligonucleotide. 3 is attached to the 3' carbon of the single stranded oligonucleotide. 3 is attached to the 3' carbon of the 3' terminal nucleotide of the double-stranded or single-stranded oligonucleotide. 3 is attached to the 3' carbon of the 3' terminal nucleotide of the double-stranded oligonucleotide. 3 is attached to the 3' carbon of the 3' terminal nucleotide of the single stranded oligonucleotide.

[0116] In an embodiment, one L 3is attached to the 5' carbon of the double-stranded or single-stranded oligonucleotide. 3 is attached to the 5' carbon of the double stranded oligonucleotide. 3 is attached to the 5' carbon of the single stranded oligonucleotide. 3 is attached to the 5' carbon of the 5' terminal nucleotide of the double-stranded or single-stranded oligonucleotide. 3 is attached to the 5' carbon of the 5' terminal nucleotide of the double-stranded oligonucleotide. 3 is attached to the 5' carbon of the 5' terminal nucleotide of the single stranded oligonucleotide.

[0117] In an embodiment, one L 3 is attached to the 2' carbon of a nucleotide of the double stranded oligonucleotide. 3 is attached to the 2' carbon of a nucleotide of the single stranded oligonucleotide. In embodiments, the 2' carbon is the 2' carbon of an internal nucleotide.

[0118] In an embodiment, one L 3 is connected to the nucleobase of the double-stranded or single-stranded oligonucleotide. 3 is connected to the nucleobase of the double-stranded oligonucleotide. 3 is attached to the nucleobase of the single-stranded oligonucleotide.

[0119] In an embodiment, L 3 and L 4 each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 In embodiments, L is -O-, a substituted or unsubstituted alkylene, or a substituted or unsubstituted heteroalkylene. 3each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 In embodiments, L is -O-, a substituted or unsubstituted alkylene, or a substituted or unsubstituted heteroalkylene. 4 each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.

[0120] In an embodiment, L 3 is independently a bond. In embodiments, L 3 is independently -NH-. In embodiments, L 3 is independently -O-. In embodiments, L 3 is independently -S-. In embodiments, L 3 is independently -C(O)-. In embodiments, L 3 is independently -NHC(O)-. In embodiments, L 3 is independently -NHC(O)NH-. In embodiments, L 3 is independently -C(O)O-. In embodiments, L 3 is independently -OC(O)-. In embodiments, L 3 is independently -C(O)NH-. In embodiments, L 3 independently, -OPO 2 In embodiments, L 3 is independently substituted or unsubstituted alkylene. In embodiments, L 3 is independently substituted or unsubstituted heteroalkylene.

[0121] In an embodiment, L 3 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 3 are independently substituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 3 are independently unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 3 are independently substituted or unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 3 is independently a substitution C 1 -C 20 In embodiments, L is an alkylene. 3 are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 3 are independently substituted or unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 3 is independently a substitution C 1 -C 12 In embodiments, L is an alkylene. 3 are independently unsubstituted C 1 -C 12In embodiments, L is an alkylene. 3 are independently substituted or unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 3 is independently a substitution C 1 -C 8 In embodiments, L is an alkylene. 3 are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 3 are independently substituted or unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 3 is independently a substitution C 1 -C 6 In embodiments, L is an alkylene. 3 are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 3 are independently substituted or unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 3 is independently a substitution C 1 -C 4 In embodiments, L is an alkylene. 3 are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 3 is independently substituted or unsubstituted ethylene. In embodiments, L 3 is independently a substituted ethylene. 3 is independently unsubstituted ethylene. In embodiments, L 3 is independently substituted or unsubstituted methylene. In embodiments, L 3 is independently a substituted methylene. 3 is independently unsubstituted methylene.

[0122] In an embodiment, L 3is independently a substituted or unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 3 is independently a substituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 3 is independently an unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 3 is independently a substituted or unsubstituted 2-20 membered heteroalkylene. 3 is independently a substituted 2-20 membered heteroalkylene. 3 is independently an unsubstituted 2- to 20-membered heteroalkylene. 3 is independently a substituted or unsubstituted 2-8 membered heteroalkylene. 3 is independently a substituted 2-8 membered heteroalkylene. 3 is independently an unsubstituted 2-8 membered heteroalkylene. 3 is independently a substituted or unsubstituted 2-6 membered heteroalkylene. 3 is independently a substituted 2-6 membered heteroalkylene. 3 is independently an unsubstituted 2-6 membered heteroalkylene. 3 is independently a substituted or unsubstituted 4- to 6-membered heteroalkylene. 3 is independently a substituted 4- to 6-membered heteroalkylene. 3 is independently an unsubstituted 4- to 6-membered heteroalkylene. 3 is independently a substituted or unsubstituted 2-3 membered heteroalkylene. 3 is independently a substituted 2-3 membered heteroalkylene. 3is independently an unsubstituted 2-3 membered heteroalkylene. 3 is independently a substituted or unsubstituted 4- to 5-membered heteroalkylene. 3 is independently a substituted 4- to 5-membered heteroalkylene. 3 are independently unsubstituted 4- to 5-membered heteroalkylene.

[0123] In an embodiment, L 4 is independently a bond. In embodiments, L 4 is independently -NH-. In embodiments, L 4 is independently -O-. In embodiments, L 4 is independently -S-. In embodiments, L 4 is independently -C(O)-. In embodiments, L 4 is independently -NHC(O)-. In embodiments, L 4 is independently -NHC(O)NH-. In embodiments, L 4 is independently -C(O)O-. In embodiments, L 4 is independently -OC(O)-. In embodiments, L 4 is independently -C(O)NH-. In embodiments, L 4 independently, -OPO 2 In embodiments, L 4 is independently substituted or unsubstituted alkylene. In embodiments, L 4 is independently substituted or unsubstituted heteroalkylene.

[0124] In an embodiment, L 4 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C2 In an embodiment, L 4 are independently substituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 4 are independently unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 4 are independently substituted or unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 4 is independently a substitution C 1 -C 20 In embodiments, L is an alkylene. 4 are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 4 are independently substituted or unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 4 is independently a substitution C 1 -C 12 In embodiments, L is an alkylene. 4 are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 4 are independently substituted or unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 4 is independently a substitution C1 -C 8 In embodiments, L is an alkylene. 4 are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 4 are independently substituted or unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 4 is independently a substitution C 1 -C 6 In embodiments, L is an alkylene. 4 are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 4 are independently substituted or unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 4 is independently a substitution C 1 -C 4 In embodiments, L is an alkylene. 4 are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 4 is independently substituted or unsubstituted ethylene. In embodiments, L 4 is independently a substituted ethylene. 4 is independently unsubstituted ethylene. In embodiments, L 4 is independently substituted or unsubstituted methylene. In embodiments, L 4 is independently a substituted methylene. 4 is independently unsubstituted methylene.

[0125] In an embodiment, L 4 is independently a substituted or unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 4is independently a substituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 4 is independently an unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 4 is independently a substituted or unsubstituted 2-20 membered heteroalkylene. 4 is independently a substituted 2-20 membered heteroalkylene. 4 is independently an unsubstituted 2- to 20-membered heteroalkylene. 4 is independently a substituted or unsubstituted 2-8 membered heteroalkylene. 4 is independently a substituted 2-8 membered heteroalkylene. 4 is independently an unsubstituted 2-8 membered heteroalkylene. 4 is independently a substituted or unsubstituted 2-6 membered heteroalkylene. 4 is independently a substituted 2-6 membered heteroalkylene. 4 is independently an unsubstituted 2-6 membered heteroalkylene. 4 is independently a substituted or unsubstituted 4- to 6-membered heteroalkylene. 4 is independently a substituted 4- to 6-membered heteroalkylene. 4 is independently an unsubstituted 4- to 6-membered heteroalkylene. 4 is independently a substituted or unsubstituted 2-3 membered heteroalkylene. 4 is independently a substituted 2-3 membered heteroalkylene. 4 is independently an unsubstituted 2-3 membered heteroalkylene. 4 is independently a substituted or unsubstituted 4- to 5-membered heteroalkylene. 4is independently a substituted 4- to 5-membered heteroalkylene. 4 are independently unsubstituted 4- to 5-membered heteroalkylene.

[0126] In an embodiment, L 3 is, independently, [ka] In an embodiment, L 3 independently, -OPO 2 In embodiments, L 3 are independently -O-.

[0127] In an embodiment, L 4 is independently substituted or unsubstituted alkylene or substituted or unsubstituted heteroalkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 In an embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 7 are independently substituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 7 are independently unsubstituted alkylene (e.g., C 1-C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).

[0128] In an embodiment, L 4 is independently a substituted or unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 4 is independently a substituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 4 is independently an oxo-substituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 4 is independently an unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring).

[0129] In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 4 is independently -L 7 -NH-C(O)-, L 7are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 4 is independently -L 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).

[0130] In an embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 7 are independently substituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L7 are independently unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 7 are independently substituted or unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 7 is independently a substitution C 1 -C 20 In embodiments, L is an alkylene. 7 are independently hydroxy (OH) substituted C 1 -C 20 In embodiments, L is an alkylene. 7 is independently a hydroxymethyl-substituted C 1 -C 20 In embodiments, L is an alkylene. 7 are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 7 are independently substituted or unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 7 is independently a substitution C 1 -C 12 In embodiments, L is an alkylene. 7 are independently hydroxy (OH) substituted C 1 -C 12 In embodiments, L is an alkylene. 7 is independently a hydroxymethyl-substituted C 1 -C 12 In embodiments, L is an alkylene. 7 are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 7 are independently substituted or unsubstituted C 1 -C8 In embodiments, L is an alkylene. 7 is independently a substitution C 1 -C 8 In embodiments, L is an alkylene. 7 are independently hydroxy (OH) substituted C 1 -C 8 In embodiments, L is an alkylene. 7 is independently a hydroxymethyl-substituted C 1 -C 8 In embodiments, L is an alkylene. 7 are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 7 are independently substituted or unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 7 is independently a substitution C 1 -C 6 In embodiments, L is an alkylene. 7 are independently hydroxy (OH) substituted C 1 -C 6 In embodiments, L is an alkylene. 7 is independently a hydroxymethyl-substituted C 1 -C 6 In embodiments, L is an alkylene. 7 are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 7 are independently substituted or unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 7 is independently a substitution C 1 -C 4 In embodiments, L is an alkylene. 7 are independently hydroxy (OH) substituted C 1 -C 4 In embodiments, L is an alkylene. 7 is independently a hydroxymethyl-substituted C 1 -C 4 In embodiments, L is an alkylene. 7 are independently unsubstituted C1 -C 4 In embodiments, L is an alkylene. 7 are independently substituted or unsubstituted C 1 -C 2 In embodiments, L is an alkylene. 7 is independently a substitution C 1 -C 2 In embodiments, L is an alkylene. 7 are independently hydroxy (OH) substituted C 1 -C 2 In embodiments, L is an alkylene. 7 is independently a hydroxymethyl-substituted C 1 -C 2 In embodiments, L is an alkylene. 7 are independently unsubstituted C 1 -C 2 It is alkylene.

[0131] In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7is independently a substitution C 1 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 1 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 1 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently unsubstituted C 1 -C 8 It is alkylene.

[0132] In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 3 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a substitution C 3 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 3 -C 8 In embodiments, L is an alkylene.4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 3 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently unsubstituted C 3 -C 8 It is alkylene.

[0133] In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 5 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a substitution C 5 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 5 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 5 -C 8 In embodiments, L is an alkylene. 4 is independently -L 7 -NH-C(O)- or -L 7-C(O)-NH-, L 7 are independently unsubstituted C 5 -C 8 It is alkylene.

[0134] In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently substituted or unsubstituted octylene. In embodiments, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a substituted octylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a hydroxy (OH) substituted octylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently unsubstituted octylene. In embodiments, L 4 is independently -L 7 -NH-C(O)-, L 7 is independently a hydroxy (OH) substituted octylene. 4 is independently -L 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted octylene. 4 is independently -L 7 -NH-C(O), L 7 is independently unsubstituted octylene.

[0135] In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L7 is independently substituted or unsubstituted heptylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a substituted heptylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a hydroxy (OH) substituted heptylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently unsubstituted heptylene. In embodiments, L 4 is independently -L 7 -NH-C(O)-, L 7 is independently a hydroxy (OH) substituted heptylene. 4 is independently -L 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted heptylene. 4 is independently -L 7 -NH-C(O), L 7 is independently unsubstituted heptylene.

[0136] In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently substituted or unsubstituted hexylene. In embodiments, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a substituted hexylene. 4 is independently -L 7-NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a hydroxy (OH) substituted hexylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently unsubstituted hexylene. In embodiments, L 4 is independently -L 7 -NH-C(O)-, L 7 is independently a hydroxy (OH) substituted hexylene. 4 is independently -L 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted hexylene. 4 is independently -L 7 -NH-C(O), L 7 is independently unsubstituted hexylene.

[0137] In an embodiment, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently substituted or unsubstituted pentylene. In embodiments, L 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a substituted pentylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently a hydroxy (OH) substituted pentylene. 4 is independently -L 7 -NH-C(O)- or -L 7 -C(O)-NH-, L 7 is independently unsubstituted pentylene. In embodiments, L4 is independently -L 7 -NH-C(O)-, L 7 is independently a hydroxy (OH) substituted pentylene. 4 is independently -L 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted pentylene. 4 is independently -L 7 -NH-C(O), L 7 is independently unsubstituted pentylene.

[0138] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] It is.

[0139] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] In an embodiment, L 4 is, independently, [ka] It is.

[0140] In an embodiment, -L 3 -L 4 - is, independently, -L 7 -NH-C(O)- or -L 7 In an embodiment, L 7 is independently a substituted or unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7 is independently a substituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7 is independently an oxo-substituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7is independently an unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7 is independently a substituted or unsubstituted heteroalkenylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7 is independently a substituted heteroalkenylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7 is independently an oxo-substituted heteroalkenylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7 is independently an unsubstituted heteroalkenylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring).

[0141] In an embodiment, L 7 is independently a substituted or unsubstituted 2-20 membered heteroalkylene. 7 is independently a substituted 2-20 membered heteroalkylene. 7 is independently an oxo-substituted 2-20 membered heteroalkylene. 7 is independently an unsubstituted 2- to 20-membered heteroalkylene. 7 is independently a substituted or unsubstituted 2-12 membered heteroalkylene. 7 is independently a substituted 2- to 12-membered heteroalkylene. 7 is independently an oxo-substituted 2- to 12-membered heteroalkylene. 7 is independently an unsubstituted 2- to 12-membered heteroalkylene. 7 is independently a substituted or unsubstituted 2-10 membered heteroalkylene. 7 is independently a substituted 2-10 membered heteroalkylene.7 is independently an oxo-substituted 2-10 membered heteroalkylene. 7 is independently an unsubstituted 2-10 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2-8 membered heteroalkylene. 7 is independently a substituted 2-8 membered heteroalkylene. 7 is independently an oxo-substituted 2-8 membered heteroalkylene. 7 is independently an unsubstituted 2-8 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2-6 membered heteroalkylene. 7 is independently a substituted 2-6 membered heteroalkylene. 7 is independently an oxo-substituted 2-6 membered heteroalkylene. 7 is independently an unsubstituted 2-6 membered heteroalkylene. 7 is independently a substituted or unsubstituted 2-4 membered heteroalkylene. 7 is independently a substituted 2-4 membered heteroalkylene. 7 is independently an oxo-substituted 2-4 membered heteroalkylene. 7 is independently an unsubstituted 2-4 membered heteroalkylene.

[0142] In an embodiment, L 7 is independently a substituted or unsubstituted 2-20 membered heteroalkenylene. 7 is independently a substituted 2-20 membered heteroalkenylene. 7 is independently an oxo-substituted 2-20 membered heteroalkenylene. 7 is independently an unsubstituted 2-20 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2-12 membered heteroalkenylene.7 is independently a substituted 2-12 membered heteroalkenylene. 7 is independently an oxo-substituted 2- to 12-membered heteroalkenylene. 7 is independently an unsubstituted 2-12 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2-10 membered heteroalkenylene. 7 is independently a substituted 2-10 membered heteroalkenylene. 7 is independently an oxo-substituted 2-10 membered heteroalkenylene. 7 is independently an unsubstituted 2-10 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2-8 membered heteroalkenylene. 7 is independently a substituted 2-8 membered heteroalkenylene. 7 is independently an oxo-substituted 2-8 membered heteroalkenylene. 7 is independently an unsubstituted 2-8 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2-6 membered heteroalkenylene. 7 is independently a substituted 2-6 membered heteroalkenylene. 7 is independently an oxo-substituted 2-6 membered heteroalkenylene. 7 is independently an unsubstituted 2-6 membered heteroalkenylene. 7 is independently a substituted or unsubstituted 2-4 membered heteroalkenylene. 7 is independently a substituted 2-4 membered heteroalkenylene. 7 is independently an oxo-substituted 2-4 membered heteroalkenylene. 7 is independently an unsubstituted 2-4 membered heteroalkenylene.

[0143] In an embodiment, -L3 -L 4 - is, independently, -OL 7 -NH-C(O)- or -OL 7 In an embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)- or -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O), L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, -L 3 -L 4- is, independently, -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).

[0144] In an embodiment, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 is independently a substitution C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently unsubstituted C 1 -C 8It is alkylene.

[0145] In an embodiment, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 is independently a substitution C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently unsubstituted C 3 -C 8 It is alkylene.

[0146] In an embodiment, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7-C(O)-NH-, L 7 is independently a substitution C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -C(O)-NH-, L 7 are independently unsubstituted C 5 -C 8 It is alkylene.

[0147] In an embodiment, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently substituted or unsubstituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 is independently a substitution C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently hydroxy (OH) substituted C 1 -C 8 In embodiments, -L 3 -L 4- is, independently, -OL 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently unsubstituted C 1 -C 8 It is alkylene.

[0148] In an embodiment, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently substituted or unsubstituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 is independently a substitution C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently hydroxy (OH) substituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently unsubstituted C 3 -C 8 It is alkylene.

[0149] In an embodiment, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently substituted or unsubstituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 is independently a substitution C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently hydroxy (OH) substituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OL 7 -NH-C(O)-, L 7 are independently unsubstituted C 5 -C 8 It is alkylene.

[0150] In an embodiment, -L 3 -L 4 - is, independently, [ka] In an embodiment, -L 3 -L 4 - is, independently, [ka] In an embodiment, -L 3 -L 4 - is, independently, [ka] In an embodiment, -L 3 -L 4 - is, independently, [ka] It is.

[0151] In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)- or -OPO 2 -OL 7 In an embodiment, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)- or -OPO 2 -OL 7 -C(O)-NH-, L 7 is independently a substituted or unsubstituted alkylene. In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O), L 7 is independently a substituted or unsubstituted alkylene. In embodiments, -L 3 -L 4- is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 is independently a substituted or unsubstituted alkylene. In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)- or -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).

[0152] In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 is independently a substitution C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently unsubstituted C 1 -C 8 It is alkylene.

[0153] In an embodiment, -L 3 -L 4- is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 is independently a substitution C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently unsubstituted C 3 -C 8 It is alkylene.

[0154] In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently substituted or unsubstituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO2 -OL 7 -C(O)-NH-, L 7 is independently a substitution C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently hydroxy (OH) substituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 is independently a hydroxymethyl-substituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -C(O)-NH-, L 7 are independently unsubstituted C 5 -C 8 It is alkylene.

[0155] In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 are independently substituted or unsubstituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 is independently a substitution C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL7 -NH-C(O)-, L 7 are independently hydroxy (OH) substituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted C 1 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 are independently unsubstituted C 1 -C 8 It is alkylene.

[0156] In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 are independently substituted or unsubstituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 is independently a substitution C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 are independently hydroxy (OH) substituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7-NH-C(O)-, L 7 is independently a hydroxymethyl-substituted C 3 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 are independently unsubstituted C 3 -C 8 It is alkylene.

[0157] In an embodiment, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 are independently substituted or unsubstituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 is independently a substitution C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 are independently hydroxy (OH) substituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7 -NH-C(O)-, L 7 is independently a hydroxymethyl-substituted C 5 -C 8 In embodiments, -L 3 -L 4 - is, independently, -OPO 2 -OL 7-NH-C(O)-, L 7 are independently unsubstituted C 5 -C 8 It is alkylene.

[0158] In an embodiment, -L 3 -L 4 - is, independently, [ka] In an embodiment, -L 3 -L 4 - is, independently, [ka] and is attached to the 3' carbon of the double-stranded or single-stranded oligonucleotide. In an embodiment, -L 3 -L 4 - is, independently, [ka] and is attached to the 5' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 2' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the nucleobase of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 3' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 5' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 2' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the nucleobase of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 3' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 5' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 2' carbon of the double-stranded or single-stranded oligonucleotide.3 -L 4 - is, independently, [ka] and is attached to the nucleobase of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 3' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 5' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the 2' carbon of the double-stranded or single-stranded oligonucleotide. 3 -L 4 - is, independently, [ka] and is attached to the nucleobase of a double-stranded or single-stranded oligonucleotide.

[0159] In embodiments, R 3 are independently hydrogen, -NH 2 , -OH, -SH, -C(O)H, -C(O)NH 2 , -NHC(O)H, -NHC(O)OH, -NHC(O)NH 2 , -C(O)OH, -OC(O)H, -N 3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. 3 is independently hydrogen. In embodiments, R 3 are independently -NH 2 In an embodiment, R 3 is independently -OH. In embodiments, R 3 is independently -SH. In embodiments, R 3 is independently -C(O)H. In embodiments, R 3 are independently -C(O)NH 2 In an embodiment, R 3 is independently -NHC(O)H. In embodiments, R 3 is independently -NHC(O)OH. In embodiments, R 3 are independently -NHC(O)NH 2 In an embodiment, R 3 is independently -C(O)OH. In embodiments, R 3 is independently -OC(O)H. In embodiments, R 3 are independent of each other, -N 3 It is.

[0160] In embodiments, R 3 are independently substituted or unsubstituted alkyl (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 3 are independently substituted or unsubstituted C 1 -C 20 In embodiments, R 3 is independently a substitution C 1 -C20 In embodiments, R 3 are independently unsubstituted C 1 -C 20 In embodiments, R 3 are independently substituted or unsubstituted C 1 -C 12 In embodiments, R 3 is independently a substitution C 1 -C 12 In embodiments, R 3 are independently unsubstituted C 1 -C 12 In embodiments, R 3 are independently substituted or unsubstituted C 1 -C 8 In embodiments, R 3 is independently a substitution C 1 -C 8 In embodiments, R 3 are independently unsubstituted C 1 -C 8 In embodiments, R 3 are independently substituted or unsubstituted C 1 -C 6 In embodiments, R 3 is independently a substitution C 1 -C 6 In embodiments, R 3 are independently unsubstituted C 1 -C 6 In embodiments, R 3 are independently substituted or unsubstituted C 1 -C 4 In embodiments, R 3 is independently a substitution C 1 -C 4 In embodiments, R 3 are independently unsubstituted C 1 -C 4 In embodiments, R 3 is independently substituted or unsubstituted ethyl. In embodiments, R 3is independently substituted ethyl. In embodiments, R 3 is independently unsubstituted ethyl. In embodiments, R 3 is independently substituted or unsubstituted methyl. In embodiments, R 3 is independently a substituted methyl. In embodiments, R 3 is independently unsubstituted methyl.

[0161] In an embodiment, L 6 is independently -NHC(O)-. In embodiments, L 6 is independently -C(O)NH-. In embodiments, L 6 is independently substituted or unsubstituted alkylene. In embodiments, L 6 is independently substituted or unsubstituted heteroalkylene.

[0162] In an embodiment, L 6 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 6 are independently substituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 6 are independently unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 6 are independently substituted or unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 6 is independently a substitution C 1 -C 20 In embodiments, L is an alkylene. 6 are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 6 are independently substituted or unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 6 is independently a substitution C 1 -C 12 In embodiments, L is an alkylene. 6 are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 6 are independently substituted or unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 6 is independently a substitution C 1 -C 8 In embodiments, L is an alkylene. 6 are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 6 are independently substituted or unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 6 is independently a substitution C 1 -C 6 In embodiments, L is an alkylene. 6 are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 6 are independently substituted or unsubstituted C 1-C 4 In embodiments, L is an alkylene. 6 is independently a substitution C 1 -C 4 In embodiments, L is an alkylene. 6 are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 6 is independently substituted or unsubstituted ethylene. In embodiments, L 6 is independently a substituted ethylene. 6 is independently unsubstituted ethylene. In embodiments, L 6 is independently substituted or unsubstituted methylene. In embodiments, L 6 is independently a substituted methylene. 6 is independently unsubstituted methylene.

[0163] In an embodiment, L 6 is independently a substituted or unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 6 is independently a substituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 6 is independently an unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 6 is independently a substituted or unsubstituted 2-20 membered heteroalkylene. 6 is independently a substituted 2-20 membered heteroalkylene. 6 is independently an unsubstituted 2- to 20-membered heteroalkylene. 6 is independently a substituted or unsubstituted 2-8 membered heteroalkylene. 6 is independently a substituted 2-8 membered heteroalkylene. 6is independently an unsubstituted 2-8 membered heteroalkylene. 6 is independently a substituted or unsubstituted 2-6 membered heteroalkylene. 6 is independently a substituted 2-6 membered heteroalkylene. 6 is independently an unsubstituted 2-6 membered heteroalkylene. 6 is independently a substituted or unsubstituted 4- to 6-membered heteroalkylene. 6 is independently a substituted 4- to 6-membered heteroalkylene. 6 is independently an unsubstituted 4- to 6-membered heteroalkylene. 6 is independently a substituted or unsubstituted 2-3 membered heteroalkylene. 6 is independently a substituted 2-3 membered heteroalkylene. 6 is independently an unsubstituted 2-3 membered heteroalkylene. 6 is independently a substituted or unsubstituted 4- to 5-membered heteroalkylene. 6 is independently a substituted 4- to 5-membered heteroalkylene. 6 are independently unsubstituted 4- to 5-membered heteroalkylene.

[0164] In an embodiment, L 6A are independently a bond or unsubstituted alkylene; L 6B are independently a bond, -NHC(O)-, or unsubstituted arylene; L 6C are independently a bond, unsubstituted alkylene, or unsubstituted arylene; L 6D are independently a bond or unsubstituted alkylene; L 6E is independently a bond or -NHC(O)-. In embodiments, L 6A is independently a bond or unsubstituted alkylene. 6B is independently a bond, -NHC(O)-, or unsubstituted arylene. 6Cis independently a bond, an unsubstituted alkylene, or an unsubstituted arylene. 6D is independently a bond or unsubstituted alkylene. 6E is independently a bond or -NHC(O)-.

[0165] In an embodiment, L 6A are independently a bond or an unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 6A are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 6A are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 6A are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 6A are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 6A are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 6A is independently unsubstituted ethylene. In embodiments, L 6A is independently unsubstituted methylene. In embodiments, L 6A are independently bonds.

[0166] In an embodiment, L 6B is independently a bond. In embodiments, L 6B is independently -NHC(O)-. In embodiments, L 6Bare independently unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl). In embodiments, L 6B are independently unsubstituted C 6 -C 12 In embodiments, L is arylene. 6B are independently unsubstituted C 6 -C 10 In embodiments, L is arylene. 6B is independently unsubstituted phenylene. In embodiments, L 6B is independently unsubstituted naphthylene.

[0167] In an embodiment, L 6C are independently a bond or an unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 6C are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 6C are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 6C are independently unsubstituted C 1 -C 8 It is alkylene. 6C are independently unsubstituted C 2 -C 8 In embodiments, L is alkynylene. 6C are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 6C are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene.6C is independently unsubstituted ethylene. In embodiments, L 6C is independently unsubstituted methylene. In embodiments, L 6C are independently a bond or unsubstituted alkynylene (e.g., C 2 -C 20 , C 2 -C 12 , C 2 -C 8 , C 2 -C 6 , C 2 -C 4 , or C 2 -C 2 In an embodiment, L 6C are independently unsubstituted C 2 -C 20 In embodiments, L is alkynylene. 6C are independently unsubstituted C 2 -C 12 In embodiments, L is alkynylene. 6C are independently unsubstituted C 2 -C 8 In embodiments, L is alkynylene. 6C are independently unsubstituted C 2 -C 6 In embodiments, L is alkynylene. 6C are independently unsubstituted C 2 -C 4 In embodiments, L is alkynylene. 6C is independently unsubstituted ethynylene. In embodiments, L 6C are independently unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl). In embodiments, L 6C are independently unsubstituted C 6 -C 12 In embodiments, L is arylene. 6C are independently unsubstituted C 6 -C 10 In embodiments, L is arylene. 6C is independently unsubstituted phenylene. In embodiments, L6C is independently unsubstituted naphthylene. In embodiments, L 6C are independently bonds.

[0168] In an embodiment, L 6D are independently a bond or an unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 6D are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 6D are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 6A are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 6D are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 6D are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 6D is independently unsubstituted ethylene. In embodiments, L 6D is independently unsubstituted methylene. In embodiments, L 6D are independently bonds.

[0169] In an embodiment, L 6E is independently a bond. In embodiments, L 6E are independently -NHC(O)-.

[0170] In an embodiment, L 6A are independently a bond or an unsubstituted C 1 -C8 In embodiments, L is an alkylene. 6B is independently a bond, -NHC(O)-, or unsubstituted phenylene. 6C are independently a bond, an unsubstituted C 2 -C 8 In embodiments, L is alkynylene, or unsubstituted phenylene. 6D are independently a bond or an unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 6E is independently a bond or -NHC(O)-.

[0171] In an embodiment, L 6 are independent, combined, [ka] In an embodiment, L 6 is independently a bond. In embodiments, L 6 is, independently, [ka] In an embodiment, L 6 is, independently, [ka] In an embodiment, L 6 is, independently, [ka] In an embodiment, L 6 is, independently, [ka] In an embodiment, L 6 is, independently, [ka] It is.

[0172] In an embodiment, L 5 is independently -NHC(O)-. In embodiments, L 5 is independently -C(O)NH-. In embodiments, L 5 is independently a substituted or unsubstituted alkylene. 5 is independently substituted or unsubstituted heteroalkylene.

[0173] In an embodiment, L 5 are independently substituted or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 5 are independently substituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 5 are independently unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 5 are independently substituted or unsubstituted C 1 -C 20 In embodiments, L is an alkylene.5 is independently a substitution C 1 -C 20 In embodiments, L is an alkylene. 5 are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 5 are independently substituted or unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 5 is independently a substitution C 1 -C 12 In embodiments, L is an alkylene. 5 are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 5 are independently substituted or unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 5 is independently a substitution C 1 -C 8 In embodiments, L is an alkylene. 5 are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 5 are independently substituted or unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 5 is independently a substitution C 1 -C 6 In embodiments, L is an alkylene. 5 are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 5 are independently substituted or unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 5 is independently a substitution C 1 -C 4 In embodiments, L is an alkylene. 5 are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 5is independently substituted or unsubstituted ethylene. In embodiments, L 5 is independently a substituted ethylene. 5 is independently unsubstituted ethylene. In embodiments, L 5 is independently substituted or unsubstituted methylene. In embodiments, L 5 is independently a substituted methylene. 5 is independently unsubstituted methylene.

[0174] In an embodiment, L 5 is independently a substituted or unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 5 is independently a substituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 5 is independently an unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 5 is independently a substituted or unsubstituted 2- to 20-membered heteroalkylene. 5 is independently a substituted 2-20 membered heteroalkylene. 5 is independently an unsubstituted 2- to 20-membered heteroalkylene. 5 is independently a substituted or unsubstituted 2-8 membered heteroalkylene. 5 is independently a substituted 2-8 membered heteroalkylene. 5 is independently an unsubstituted 2-8 membered heteroalkylene. 5 is independently a substituted or unsubstituted 2-6 membered heteroalkylene. 5 is independently a substituted 2-6 membered heteroalkylene. 5is independently an unsubstituted 2-6 membered heteroalkylene. 5 is independently a substituted or unsubstituted 4- to 6-membered heteroalkylene. 5 is independently a substituted 4- to 6-membered heteroalkylene. 5 is independently an unsubstituted 4- to 6-membered heteroalkylene. 5 is independently a substituted or unsubstituted 2-3 membered heteroalkylene. 5 is independently a substituted 2-3 membered heteroalkylene. 5 is independently an unsubstituted 2-3 membered heteroalkylene. 5 is independently a substituted or unsubstituted 4- to 5-membered heteroalkylene. 6 is independently a substituted 4- to 5-membered heteroalkylene. 6 are independently unsubstituted 4- to 5-membered heteroalkylene.

[0175] In an embodiment, L 5A are independently a bond or unsubstituted alkylene; L 5B are independently a bond, -NHC(O)-, or unsubstituted arylene; L 5C are independently a bond, unsubstituted alkylene, or unsubstituted arylene; L 5D are independently a bond or unsubstituted alkylene; L 5E is independently a bond or -NHC(O)-. In embodiments, L 5A is independently a bond or unsubstituted alkylene. 5B is independently a bond, -NHC(O)-, or unsubstituted arylene. 5C is independently a bond, an unsubstituted alkylene, or an unsubstituted arylene. 5D is independently a bond or unsubstituted alkylene. 5E is independently a bond or -NHC(O)-.

[0176] In an embodiment, L 5A are independently a bond or an unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 5A are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 5A are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 5A are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 5A are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 5A are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 5A is independently unsubstituted ethylene. In embodiments, L 5A is independently unsubstituted methylene. In embodiments, L 5A are independently bonds.

[0177] In an embodiment, L 5B is independently a bond. In embodiments, L 5B is independently -NHC(O)-. In embodiments, L 5B are independently unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl). In embodiments, L 5B are independently unsubstituted C 6 -C 12In embodiments, L is arylene. 5B are independently unsubstituted C 6 -C 10 In embodiments, L is arylene. 5B is independently unsubstituted phenylene. In embodiments, L 5B is independently unsubstituted naphthylene.

[0178] In an embodiment, L 5C are independently a bond or an unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 5C are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 5C are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 5C are independently unsubstituted C 1 -C 8 It is alkylene. 5C are independently unsubstituted C 2 -C 8 In embodiments, L is alkynylene. 5C are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 5C are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 5C is independently unsubstituted ethylene. In embodiments, L 5C is independently unsubstituted methylene. In embodiments, L 5C are independently a bond or unsubstituted alkynylene (e.g., C 2 -C 20 , C2 -C 12 , C 2 -C 8 , C 2 -C 6 , C 2 -C 4 , or C 2 -C 2 In an embodiment, L 5C are independently unsubstituted C 2 -C 20 In embodiments, L is alkynylene. 5C are independently unsubstituted C 2 -C 12 In embodiments, L is alkynylene. 5C are independently unsubstituted C 2 -C 8 In embodiments, L is alkynylene. 5C are independently unsubstituted C 2 -C 6 In embodiments, L is alkynylene. 5C are independently unsubstituted C 2 -C 4 In embodiments, L is alkynylene. 5C is independently unsubstituted ethynylene. In embodiments, L 5C are independently unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl). In embodiments, L 5C are independently unsubstituted C 6 -C 12 In embodiments, L is arylene. 5C are independently unsubstituted C 6 -C 10 In embodiments, L is arylene. 5C is independently unsubstituted phenylene. In embodiments, L 5C is independently unsubstituted naphthylene. In embodiments, L 5C are independently bonds.

[0179] In an embodiment, L 5D are independently a bond or an unsubstituted alkylene (e.g., C1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 5D are independently unsubstituted C 1 -C 20 In embodiments, L is an alkylene. 5D are independently unsubstituted C 1 -C 12 In embodiments, L is an alkylene. 5A are independently unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 5D are independently unsubstituted C 1 -C 6 In embodiments, L is an alkylene. 5D are independently unsubstituted C 1 -C 4 In embodiments, L is an alkylene. 5D is independently unsubstituted ethylene. In embodiments, L 5D is independently unsubstituted methylene. In embodiments, L 5D are independently bonds.

[0180] In an embodiment, L 5E is independently a bond. In embodiments, L 5E are independently -NHC(O)-.

[0181] In an embodiment, L 5A are independently a bond or an unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 5B is independently a bond, -NHC(O)-, or unsubstituted phenylene. 5C are independently a bond, an unsubstituted C 2 -C 8In embodiments, L is alkynylene, or unsubstituted phenylene. 5D are independently a bond or an unsubstituted C 1 -C 8 In embodiments, L is an alkylene. 5E is independently a bond or -NHC(O)-.

[0182] In an embodiment, L 5 are independent, combined, [ka] In an embodiment, L 5 is independently a bond. In embodiments, L 5 is, independently, [ka] In an embodiment, L 5 is, independently, [ka] In an embodiment, L 5 is, independently, [ka] In an embodiment, L 5 is, independently, [ka] In an embodiment, L 5 is, independently, [ka] It is.

[0183] In embodiments, R 1 is an unsubstituted alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 17 , C1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 1 is an unsubstituted unbranched alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 17 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 1 is an unsubstituted unbranched saturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 17 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).

[0184] In embodiments, R 1 is unsubstituted C 1 -C 17 In embodiments, R 1 is unsubstituted C 11 -C 17 In embodiments, R 1 is unsubstituted C 13 -C 17 In embodiments, R 1 is unsubstituted C 15In embodiments, R 1 is an unsubstituted unbranched C 1 -C 17 In embodiments, R 1 is an unsubstituted unbranched C 11 -C 17 In embodiments, R 1 is an unsubstituted unbranched C 13 -C 17 In embodiments, R 1 is an unsubstituted unbranched C 15 In embodiments, R 1 is an unsubstituted unbranched saturated C 1 -C 17 In embodiments, R 1 is an unsubstituted unbranched saturated C 11 -C 17 In embodiments, R 1 is an unsubstituted unbranched saturated C 13 -C 17 In embodiments, R 1 is an unsubstituted unbranched saturated C 15 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 1 -C 17 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 11 -C 17 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 13 -C 17 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 15 It is an alkyl.

[0185] In embodiments, R 2 is an unsubstituted alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 17 , C 1 -C 12 , C 1 -C 8 , C1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is an unsubstituted unbranched alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 17 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is an unsubstituted unbranched saturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 17 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).

[0186] In embodiments, R 2 is unsubstituted C 1 -C 17 In embodiments, R 2 is unsubstituted C 11 -C 17 In embodiments, R 2 is unsubstituted C 13 -C 17 In embodiments, R 2 is unsubstituted C 15 In embodiments, R 2 is an unsubstituted unbranched C 1 -C 17In embodiments, R 2 is an unsubstituted unbranched C 11 -C 17 In embodiments, R 2 is an unsubstituted unbranched C 13 -C 17 In embodiments, R 2 is an unsubstituted unbranched C 15 In embodiments, R 2 is an unsubstituted unbranched saturated C 1 -C 17 In embodiments, R 2 is an unsubstituted unbranched saturated C 11 -C 17 In embodiments, R 2 is an unsubstituted unbranched saturated C 13 -C 17 In embodiments, R 2 is an unsubstituted unbranched saturated C 15 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 1 -C 17 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 11 -C 17 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 13 -C 17 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 15 It is an alkyl.

[0187] In embodiments, R 1 and R 2 At least one of the 1 -C 19 In embodiments, R 1 and R 2 At least one of the 9 -C 19 In embodiments, R 1 and R 2 At least one of the 11 -C19 In embodiments, R 1 and R 2 At least one of the 13 -C 19 It is an alkyl.

[0188] In embodiments, R 1 is unsubstituted C 1 -C 19 In embodiments, R 1 is unsubstituted C 9 -C 19 In embodiments, R 1 is unsubstituted C 11 -C 19 In embodiments, R 1 is unsubstituted C 13 -C 19 In embodiments, R 1 is an unsubstituted unbranched C 1 -C 19 In embodiments, R 1 is an unsubstituted unbranched C 9 -C 19 In embodiments, R 1 is an unsubstituted unbranched C 11 -C 19 In embodiments, R 1 is an unsubstituted unbranched C 13 -C 19 In embodiments, R 1 is an unsubstituted unbranched saturated C 1 -C 19 In embodiments, R 1 is an unsubstituted unbranched saturated C 9 -C 19 In embodiments, R 1 is an unsubstituted unbranched saturated C 11 -C 19 In embodiments, R 1 is an unsubstituted unbranched saturated C 13 -C 19 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 1 -C 19In embodiments, R 1 is an unsubstituted unbranched unsaturated C 9 -C 19 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 11 -C 19 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 13 -C 19 It is an alkyl.

[0189] In embodiments, R 2 is unsubstituted C 1 -C 19 In embodiments, R 2 is unsubstituted C 9 -C 19 In embodiments, R 2 is unsubstituted C 11 -C 19 In embodiments, R 2 is unsubstituted C 13 -C 19 In embodiments, R 2 is an unsubstituted unbranched C 1 -C 19 In embodiments, R 2 is an unsubstituted unbranched C 9 -C 19 In embodiments, R 2 is an unsubstituted unbranched C 11 -C 19 In embodiments, R 2 is an unsubstituted unbranched C 13 -C 19 In embodiments, R 2 is an unsubstituted unbranched saturated C 1 -C 19 In embodiments, R 2 is an unsubstituted unbranched saturated C 9 -C 19 In embodiments, R 2 is an unsubstituted unbranched saturated C 11 -C 19 In embodiments, R 2is an unsubstituted unbranched saturated C 13 -C 19 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 1 -C 19 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 9 -C 19 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 11 -C 19 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 13 -C 19 It is an alkyl.

[0190] In embodiments, the oligonucleotide is an antisense oligonucleotide. In embodiments, the oligonucleotide is an siRNA. In embodiments, the oligonucleotide is a microRNA mimic. In embodiments, the oligonucleotide is a stem-loop structure. In embodiments, the oligonucleotide is a single stranded siRNA. In embodiments, the oligonucleotide is an RNaseH oligonucleotide. In embodiments, the oligonucleotide is an anti-microRNA oligonucleotide. In embodiments, the oligonucleotide is a steric hindrance oligonucleotide. In embodiments, the oligonucleotide is an aptamer. In embodiments, the oligonucleotide is a CRISPR guide RNA.

[0191] In embodiments, the oligonucleotide is a modified oligonucleotide.

[0192] In embodiments, the oligonucleotide comprises a nucleotide analogue.

[0193] In an embodiment, the oligonucleotide comprises a locked nucleic acid (LNA) residue, a constrained ethyl (cEt) residue, a bicyclic nucleic acid (BNA) residue, an unlocked nucleic acid (UNA) residue, a phosphorodiamidate morpholino oligomer (PMO) monomer, a peptide nucleic acid (PNA) monomer, a 2'-O-methyl (2'-OMe) residue, a 2'-O-methyoxyethyl residue, a 2'-deoxy-2'-fluoro residue, a 2'-O-methoxyethyl / phosphorothioate residue, a phosphoramidate, a phosphorodiamidate, a phosphorothioate, a phosphorodithioate, a phosphonocarboxylic acid, a phosphonocarboxylate, a phosphonoacetic acid, a phosphonoformic acid, a methylphosphonic acid, a boron phosphonate, or an O-methyl phosphoramidite. In an embodiment, the oligonucleotide comprises a bicyclic nucleic acid (BNA) residue. In an embodiment, the bicyclic nucleic acid residue is a locked nucleic acid (LNA). In an embodiment, the bicyclic nucleic acid (BNA) residue is a constrained ethyl (cEt) residue. In embodiments, the oligonucleotide comprises an unlocked nucleic acid (UNA) residue. In embodiments, the oligonucleotide comprises a phosphorodiamidate morpholino oligomer (PMO) monomer. In embodiments, the oligonucleotide comprises a peptide nucleic acid (PNA) monomer. In embodiments, the oligonucleotide comprises a 2'-O-methyl (2'-OMe) residue. In embodiments, the oligonucleotide comprises a 2'-O-methyoxyethyl residue. In embodiments, the oligonucleotide comprises a 2'-deoxy-2'-fluoro residue. In embodiments, the oligonucleotide comprises a 2'-O-methoxyethyl / phosphorothioate residue. In embodiments, the oligonucleotide comprises a phosphoramidate. In embodiments, the oligonucleotide comprises a phosphorodiamidate. In embodiments, the oligonucleotide comprises a phosphorothioate. In embodiments, the oligonucleotide comprises a phosphorodithioate. In embodiments, the oligonucleotide comprises a phosphonocarboxylic acid. In embodiments, the oligonucleotide comprises a phosphonocarboxylate. In embodiments, the oligonucleotide comprises a phosphonoacetic acid. In embodiments, the oligonucleotide comprises a phosphonoformic acid. In embodiments, the oligonucleotide comprises a methylphosphonate.In embodiments, the oligonucleotide comprises a boron phosphonate. In embodiments, the oligonucleotide comprises an O-methyl phosphoramidite.

[0194] In embodiments, a compound having the structure of Formula I: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide; X 1 but, [ka] And L 1 But -(CH 2 ) n -, -(CH 2 ) n L 2 (CH 2 ) n - or a bond, L 2 Provided herein are compounds in which X is -C(=O)NH-, each m is independently an integer from 10 to 18, and each n is independently an integer from 1 to 6. 1 teeth, [ka] In an embodiment, X 1 teeth, [ka] and each m is 10 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 11 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 12 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 13 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 14 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 15 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 16 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 17 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 18 and n is 3. In an embodiment, X 1 teeth, [ka] and each m is 10. In an embodiment, X 1 teeth, [ka] and each m is 11. In an embodiment, X 1 teeth, [ka] and each m is 12. In an embodiment, X 1 teeth, [ka] and each m is 13. In an embodiment, X 1 teeth, [ka] and each m is 14. In an embodiment, X 1 teeth, [ka] and each m is 15. In an embodiment, X 1 teeth, [ka] and each m is 16. In an embodiment, X 1 teeth, [ka] and each m is 17. In an embodiment, X 1 teeth, [ka] where each m is 18.

[0195] In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 10. In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 11. In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 12. In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 13. In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 14. In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 15. In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 16. In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 17. In an embodiment, X 1 teeth, [ka] And L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 18.

[0196] In an embodiment, L 1 is a bond, and each m is independently an integer from 10 to 16. 1 is a bond, and each m is independently an integer from 12 to 16. 1 is a bond, and each m is independently an integer from 12 to 14. In an embodiment, L 1 is a bond and each m is 14. In embodiments, L 1 is -(CH 2 ) n L 2 (CH 2 ) n - and L 2 is -C(=O)NH-, each m is independently an integer from 10 to 16, and each n is independently an integer from 1 to 6. 1 is -(CH 2 ) n L 2 (CH 2) n - and L 2 is -C(=O)NH-, each m is independently an integer from 12 to 16, and each n is independently an integer from 1 to 6. 1 is -(CH 2 ) n L 2 (CH 2 ) n - and L 2 is -C(=O)NH-, each m is independently an integer from 12 to 14, and each n is independently an integer from 1 to 6. 1 is -(CH 2 ) n L 2 (CH 2 ) n - and L 2 is -C(=O)NH-, each m is independently 14, and each n is independently an integer from 1 to 6. 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 -, and each m is independently an integer from 10 to 16. 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 -, and each m is independently an integer from 12 to 16. 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 -, and each m is independently an integer from 12 to 14. In an embodiment, L 1 is -(CH 2 ) 3 C(=O)NH(CH 2 ) 5 - and each m is 14. In an embodiment, each m is 14.

[0197] In embodiments, a compound having the structure of formula Ia: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide, and m is an integer from 10 to 18. The moiety of formula Ia above, represented by: [ka] is a portion of the lipid-containing moiety of formula Ia.

[0198] In embodiments, a compound having the structure of formula Ib: cet or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide, and m is an integer from 10 to 18. The moiety of formula Ib above, represented by: [ka] is a portion of the lipid-containing moiety of formula Ib.

[0199] In an embodiment of a compound having the structure of Formula I, Ia, or Ib, each m is an integer from 12 to 16. In an embodiment, each m is an integer from 12 to 14. In an embodiment, each m is 10 and L 1 Ha-(CH 2 ) n - and n is 3. In an embodiment, each m is 11 and L 1 Ha-(CH 2 ) n- and n is 3. In an embodiment, each m is 12 and L 1 Ha-(CH 2 ) n - and n is 3. In an embodiment, each m is 13 and L 1 Ha-(CH 2 ) n - and n is 3. In an embodiment, each m is 14 and L 1 Ha-(CH 2 ) n - and n is 3. In an embodiment, each m is 15 and L 1 Ha-(CH 2 ) n - and n is 3. In an embodiment, each m is 16 and L 1 Ha-(CH 2 ) n - and n is 3. In an embodiment, each m is 17 and L 1 Ha-(CH 2 ) n - and n is 3. In an embodiment, each m is 18 and L 1 Ha-(CH 2 ) n - and n is 3.

[0200] In embodiments, a lipid-conjugated compound having the structure of Formula II: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. [ka] is a portion of the lipid-containing moiety of formula II.

[0201] In embodiments, a lipid-conjugated compound having the structure of Formula IIa: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. [ka] is a portion of the lipid-containing moiety of formula IIa.

[0202] In embodiments, a lipid-conjugated compound having the structure of Formula IIb: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or the 3' end of the modified single-stranded oligonucleotide. [ka] is a portion of the lipid-containing moiety of formula IIb.

[0203] In embodiments, a lipid-conjugated compound having the structure of Formula III: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide has a Z at the 3' end of one strand of the modified double-stranded oligonucleotide or the Z at the 3' end of the modified single-stranded oligonucleotide. 1 Conjugated to Z 1 but [ka] and p is an integer from 10 to 18; The modified double-stranded oligonucleotide may have a Z at the 5' end of one strand of the modified double-stranded oligonucleotide or at the 5' end of the modified single-stranded oligonucleotide. 2 Conjugated to Z 2 but, [ka] and q is an integer from 10 to 18. In embodiments, p is 14 and q is 14.

[0204] In embodiments, a lipid-conjugated compound having the structure of Formula IIIa: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide has a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or at the 3' end of the modified single-stranded oligonucleotide. [ka] and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide. [ka] Provided herein are compounds conjugated to

[0205] In embodiments, a lipid-conjugated compound having the structure of Formula IIIb: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide has a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or at the 3' end of the modified single-stranded oligonucleotide. [ka] and the modified double-stranded or single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or at the 5' end of the modified single-stranded oligonucleotide. [ka] Provided herein are compounds conjugated to

[0206] In an embodiment, L 1 is a bond, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1-C 6 , C 1 -C 4 , or C 1 -C 2 ), or substituted (e.g., substituted, size-limited, or lower substituent) or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring). 1 is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), or substituted (e.g., substituted, size-limited, or lower substituent) or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring). 1 is a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), or substituted (e.g., substituted, size-limited, or lower-rank substituent) heteroalkylene (e.g., 2-20-membered ring, 2-12-membered ring, 2-8-membered ring, 2-6-membered ring, 4-6-membered ring, 2-3-membered ring, or 4-5-membered ring). 1 is an unsubstituted alkylene (e.g., C 1 -C 20 , C1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), or unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, a 4- to 6-membered ring, a 2- to 3-membered ring, or a 4- to 5-membered ring). 1 If is substituted, L 1 is substituted with a substituent. In embodiments, L 1 If is substituted, L 1 is substituted with size-limited substituents. 1 If is substituted, L 1 is substituted with a lower substituent.

[0207] In an embodiment, L 1 is a bond. In embodiments, L 1 is -(CH 2 ) n - or -(CH 2 ) n L 2 (CH 2 ) n In an embodiment, L 1 is -(CH 2 ) n In an embodiment, L 1 is -(CH 2 ) n L 2 (CH 2 ) n In an embodiment, n is 1 to 6. In an embodiment, n is 1 to 5. In an embodiment, n is 1 to 4. In an embodiment, n is 1 to 3. In an embodiment, n is 1 to 2. In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3. In an embodiment, n is 4. In an embodiment, n is 5. In an embodiment, n is 6.

[0208] In embodiments, each occurrence of n (i.e., n' and n") may be the same or different. In embodiments, each occurrence (i.e., n' and n") may be the same. In embodiments, each occurrence of n (i.e., n' and n") may be different. In embodiments, n' is 1 to 6. In embodiments, n' is 1 to 5. In embodiments, n' is 1 to 4. In embodiments, n' is 1 to 3. In embodiments, n' is 1 to 2. In embodiments, n' is 1. In embodiments, n' is 2. In embodiments, n' is 3. In embodiments, n' is 4. In embodiments, n' is 5. In embodiments, n' is 6. In embodiments, n" is 1 to 6. In embodiments, n" is 1 to 5. In embodiments, n" is 1 to 4. In embodiments, n" is 1 to 3. In embodiments, n" is 1 to 2. In embodiments, n" is 1. In embodiments, n" is 2. In embodiments, n" is 3. In embodiments, n" is 4. In embodiments, n" is 5. In embodiments, n" is 6.

[0209] In an embodiment, m is 10 to 18. In an embodiment, m is 10 to 17. In an embodiment, m is 10 to 16. In an embodiment, m is 10 to 15. In an embodiment, m is 10 to 14. In an embodiment, m is 10 to 13. In an embodiment, m is 10 to 12. In an embodiment, m is 10 to 11. In an embodiment, m is 10. In an embodiment, m is 11. In an embodiment, m is 12. In an embodiment, m is 13. In an embodiment, m is 14. In an embodiment, m is 15. In an embodiment, m is 16. In an embodiment, m is 17. In an embodiment, m is 18.

[0210] In an embodiment, L 2is -C(=O)NH-, -C(=O)O-, -OC(=O)O-, -NHC(=O)O-, -NHC(=O)NH-, -C(=S)NH-, -C(=O)S-, -NH-, O (oxygen), or S (sulfur). 2 is -C(=O)NH-. In embodiments, L 2 is -C(=O)O-. In embodiments, L 2 is -OC(=O)O-. In embodiments, L 2 is -NHC(=O)O-. In embodiments, L 2 is -NHC(=O)NH-. In embodiments, L 2 is -C(=S)NH. In embodiments, L 2 is -C(=O)S-. In embodiments, L 2 In embodiments, L 2 is O (oxygen). In embodiments, L 2 is S (sulfur).

[0211] L 3 each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 3 each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, substituted (e.g., substituted, size-limited, or lower substituted) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 3 each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 3 If is substituted, L 3 is substituted with a substituent. In embodiments, L 3 If is substituted, L 3 is substituted with size-limited substituents. 3 If is substituted, L 3 is substituted with a lower substituent.

[0212] L 4 each independently represents a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C2 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 4 is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, substituted (e.g., substituted, size limited or lower substituted) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C2 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 4 is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, -OPO 2 -O-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 4 If is substituted, L 4 is substituted with a substituent. In embodiments, L 4 If is substituted, L 4 is substituted with size-limited substituents. 4 If is substituted, L 4 is substituted with a lower substituent.

[0213] L 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3-C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 5 If is substituted, L 5 is substituted with a substituent. In embodiments, L 5 If is substituted, L 5 is substituted with size-limited substituents. 5 If is substituted, L 5 is substituted with a lower substituent.

[0214] L 5A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 5A If is substituted, L 5A is substituted with a substituent. In embodiments, L 5A If is substituted, L 5A is substituted with size-limited substituents. 5A If is substituted, L 5A is substituted with a lower substituent.

[0215] L 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 5B If is substituted, L 5B is substituted with a substituent. In embodiments, L 5B If is substituted, L 5B is substituted with size-limited substituents. 5B If is substituted, L 5B is substituted with a lower substituent.

[0216] L 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 5C If is substituted, L 5C is substituted with a substituent. In embodiments, L 5C If is substituted, L 5C is substituted with size-limited substituents. 5C If is substituted, L 5C is substituted with a lower substituent.

[0217] L 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 5D If is substituted, L 5D is substituted with a substituent. In embodiments, L 5D If is substituted, L 5D is substituted with size-limited substituents. 5D If is substituted, L 5D is substituted with a lower substituent.

[0218] L 5E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 5E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 5E If is substituted, L 5E is substituted with a substituent. In embodiments, L 5E If is substituted, L 5E is substituted with size-limited substituents. 5E If is substituted, L 5E is substituted with a lower substituent.

[0219] L 6 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6 are independently a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3-C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 6 If is substituted, L 6 is substituted with a substituent. In embodiments, L 6 If is substituted, L 6 is substituted with size-limited substituents. 6 If is substituted, L 6 is substituted with a lower substituent.

[0220] L 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6A is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 6A If is substituted, L 6A is substituted with a substituent. In embodiments, L 6A If is substituted, L 6A is substituted with size-limited substituents. 6A If is substituted, L 6A is substituted with a lower substituent.

[0221] L 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6B is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 6B If is substituted, L 6B is substituted with a substituent. In embodiments, L 6B If is substituted, L 6B is substituted with size-limited substituents. 6B If is substituted, L 6B is substituted with a lower substituent.

[0222] L 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6C is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 6C If is substituted, L 6C is substituted with a substituent. In embodiments, L 6C If is substituted, L 6C is substituted with size-limited substituents. 6C If is substituted, L 6C is substituted with a lower substituent.

[0223] L 6D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6D is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 6D If is substituted, L 6D is substituted with a substituent. In embodiments, L 6D If is substituted, L 6D is substituted with size-limited substituents. 6D If is substituted, L 6D is substituted with a lower substituent.

[0224] L 6E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) or unsubstituted heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkylene (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroarylene (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 6E is a bond, -NH-, -O-, -S-, -C(O)-, -NHC(O)-, -NHC(O)NH-, -C(O)O-, -OC(O)-, -C(O)NH-, unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkylene (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkylene (e.g., C 3 -C10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkylene (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted arylene (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroarylene (e.g., a 5- to 12-membered ring, a 5- to 10-membered ring, a 5- to 9-membered ring, or a 5- to 6-membered ring). 6E If is substituted, L 6E is substituted with a substituent. In embodiments, L 6E If is substituted, L 6E is substituted with size-limited substituents. 6E If is substituted, L 6E is substituted with a lower substituent.

[0225] In an embodiment, L 7 are independently substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 7 are independently substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, L 7 are independently unsubstituted alkylene (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ).

[0226] In an embodiment, L 7 is independently substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted heteroalkylene (e.g., a 2-20 membered ring, a 2-12 membered ring, a 2-10 membered ring, a 2-8 membered ring, a 2-6 membered ring, or a 2-4 membered ring). 7 is independently a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkylene (e.g., a 2-20-membered ring, a 2-12-membered ring, a 2-10-membered ring, a 2-8-membered ring, a 2-6-membered ring, or a 2-4-membered ring). 7 is independently an unsubstituted heteroalkylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7 is independently substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) or unsubstituted heteroalkenylene (e.g., a 2-20 membered ring, a 2-12 membered ring, a 2-10 membered ring, a 2-8 membered ring, a 2-6 membered ring, or a 2-4 membered ring). 7 is independently a substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkenylene (e.g., a 2-20-membered ring, a 2-12-membered ring, a 2-10-membered ring, a 2-8-membered ring, a 2-6-membered ring, or a 2-4-membered ring). 7is independently an unsubstituted heteroalkenylene (e.g., a 2- to 20-membered ring, a 2- to 12-membered ring, a 2- to 10-membered ring, a 2- to 8-membered ring, a 2- to 6-membered ring, or a 2- to 4-membered ring). 7 If is substituted, L 7 is substituted with a substituent. In embodiments, L 7 If is substituted, L 7 is substituted with size-limited substituents. 7 If is substituted, L 7 is substituted with a lower substituent.

[0227] In embodiments, R 1 is an unsubstituted alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 1 is unsubstituted C 1 -C 25 In embodiments, R 1 is unsubstituted C 1 -C 20 In embodiments, R 1 is unsubstituted C 1 -C 12 In embodiments, R 1 is unsubstituted C 1 -C 8 In embodiments, R 1 is unsubstituted C 1 -C 6 In embodiments, R 1 is unsubstituted C 1 -C 4 In embodiments, R 1 is unsubstituted C 1 -C 2 It is an alkyl.

[0228] In embodiments, R 1 is an unsubstituted branched alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 1 is an unsubstituted branch C 1 -C 25 In embodiments, R 1 is an unsubstituted branch C 1 -C 20 In embodiments, R 1 is an unsubstituted branch C 1 -C 12 In embodiments, R 1 is an unsubstituted branch C 1 -C 8 In embodiments, R 1 is an unsubstituted branch C 1 -C 6 In embodiments, R 1 is an unsubstituted branch C 1 -C 4 In embodiments, R 1 is an unsubstituted branch C 1 -C 2 It is an alkyl.

[0229] In embodiments, R 1 is an unsubstituted unbranched alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C1 -C 2 In an embodiment, R 1 is an unsubstituted unbranched C 1 -C 25 In embodiments, R 1 is an unsubstituted unbranched C 1 -C 20 In embodiments, R 1 is an unsubstituted unbranched C 1 -C 12 In embodiments, R 1 is an unsubstituted unbranched C 1 -C 8 In embodiments, R 1 is an unsubstituted unbranched C 1 -C 6 In embodiments, R 1 is an unsubstituted unbranched C 1 -C 4 In embodiments, R 1 is an unsubstituted unbranched C 1 -C 2 It is an alkyl.

[0230] In embodiments, R 1 is an unsubstituted branched saturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 1 is an unsubstituted branched saturated C 1 -C 25 In embodiments, R 1 is an unsubstituted branched saturated C 1 -C 20 In embodiments, R 1 is an unsubstituted branched saturated C 1 -C 12 In embodiments, R1 is an unsubstituted branched saturated C 1 -C 8 In embodiments, R 1 is an unsubstituted branched saturated C 1 -C 6 In embodiments, R 1 is an unsubstituted branched saturated C 1 -C 4 In embodiments, R 1 is an unsubstituted branched saturated C 1 -C 2 It is an alkyl.

[0231] In embodiments, R 1 is an unsubstituted branched unsaturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 1 is an unsubstituted branched unsaturated C 1 -C 25 In embodiments, R 1 is an unsubstituted branched unsaturated C 1 -C 20 In embodiments, R 1 is an unsubstituted branched unsaturated C 1 -C 12 In embodiments, R 1 is an unsubstituted branched unsaturated C 1 -C 8 In embodiments, R 1 is an unsubstituted branched unsaturated C 1 -C 6 In embodiments, R 1 is an unsubstituted branched unsaturated C 1 -C 4 In embodiments, R 1 is an unsubstituted branched saturated C1 -C 2 It is an alkyl.

[0232] In embodiments, R 1 is an unsubstituted unbranched saturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 1 is an unsubstituted unbranched saturated C 1 -C 25 In embodiments, R 1 is an unsubstituted unbranched saturated C 1 -C 20 In embodiments, R 1 is an unsubstituted unbranched saturated C 1 -C 12 In embodiments, R 1 is an unsubstituted unbranched saturated C 1 -C 8 In embodiments, R 1 is an unsubstituted unbranched saturated C 1 -C 6 In embodiments, R 1 is an unsubstituted unbranched saturated C 1 -C 4 In embodiments, R 1 is an unsubstituted unbranched saturated C 1 -C 2 It is an alkyl.

[0233] In embodiments, R 1 is an unsubstituted unbranched unsaturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 1 is an unsubstituted unbranched unsaturated C 1 -C 25 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 1 -C 20 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 1 -C 12 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 1 -C 8 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 1 -C 6 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 1 -C 4 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 1 -C 2 It is an alkyl.

[0234] In embodiments, R 1 is unsubstituted C 9 -C 19 In embodiments, R 1 is an unsubstituted branch C 9 -C 19 In embodiments, R 1 is an unsubstituted unbranched C 9 -C 19 In embodiments, R 1 is an unsubstituted branched saturated C 9 -C 19 In embodiments, R 1 is an unsubstituted branched unsaturated C 9 -C 19 In embodiments, R 1 is an unsubstituted unbranched saturated C9 -C 19 In embodiments, R 1 is an unsubstituted unbranched unsaturated C 9 -C 19 It is an alkyl.

[0235] In embodiments, R 2 is an unsubstituted alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is unsubstituted C 1 -C 25 In embodiments, R 2 is unsubstituted C 1 -C 20 In embodiments, R 2 is unsubstituted C 1 -C 12 In embodiments, R 2 is unsubstituted C 1 -C 8 In embodiments, R 2 is unsubstituted C 1 -C 6 In embodiments, R 2 is unsubstituted C 1 -C 4 In embodiments, R 2 is unsubstituted C 1 -C 2 It is an alkyl.

[0236] In embodiments, R 2 is an unsubstituted branched alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12, C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is an unsubstituted branch C 1 -C 25 In embodiments, R 2 is an unsubstituted branch C 1 -C 20 In embodiments, R 2 is an unsubstituted branch C 1 -C 12 In embodiments, R 2 is an unsubstituted branch C 1 -C 8 In embodiments, R 2 is an unsubstituted branch C 1 -C 6 In embodiments, R 2 is an unsubstituted branch C 1 -C 4 In embodiments, R 2 is an unsubstituted branch C 1 -C 2 It is an alkyl.

[0237] In embodiments, R 2 is an unsubstituted unbranched alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is an unsubstituted unbranched C 1 -C 25 In embodiments, R 2 is an unsubstituted unbranched C 1 -C 20In embodiments, R 2 is an unsubstituted unbranched C 1 -C 12 In embodiments, R 2 is an unsubstituted unbranched C 1 -C 8 In embodiments, R 2 is an unsubstituted unbranched C 1 -C 6 In embodiments, R 2 is an unsubstituted unbranched C 1 -C 4 In embodiments, R 2 is an unsubstituted unbranched C 1 -C 2 It is an alkyl.

[0238] In embodiments, R 2 is an unsubstituted branched saturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is an unsubstituted branched saturated C 1 -C 25 In embodiments, R 2 is an unsubstituted branched saturated C 1 -C 20 In embodiments, R 2 is an unsubstituted branched saturated C 1 -C 12 In embodiments, R 2 is an unsubstituted branched saturated C 1 -C 8 In embodiments, R 2 is an unsubstituted branched saturated C 1 -C 6 In embodiments, R 2 is an unsubstituted branched saturated C1 -C 4 In embodiments, R 2 is an unsubstituted branched saturated C 1 -C 2 It is an alkyl.

[0239] In embodiments, R 2 is an unsubstituted branched unsaturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is an unsubstituted branched unsaturated C 1 -C 25 In embodiments, R 2 is an unsubstituted branched unsaturated C 1 -C 20 In embodiments, R 2 is an unsubstituted branched unsaturated C 1 -C 12 In embodiments, R 2 is an unsubstituted branched unsaturated C 1 -C 8 In embodiments, R 2 is an unsubstituted branched unsaturated C 1 -C 6 In embodiments, R 2 is an unsubstituted branched unsaturated C 1 -C 4 In embodiments, R 2 is an unsubstituted branched unsaturated C 1 -C 2 It is an alkyl.

[0240] In embodiments, R 2 is an unsubstituted unbranched saturated alkyl (e.g., C 1 -C 25 , C 1 -C20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is an unsubstituted unbranched saturated C 1 -C 25 In embodiments, R 2 is an unsubstituted unbranched saturated C 1 -C 20 In embodiments, R 2 is an unsubstituted unbranched saturated C 1 -C 12 In embodiments, R 2 is an unsubstituted unbranched saturated C 1 -C 8 In embodiments, R 2 is an unsubstituted unbranched saturated C 1 -C 6 In embodiments, R 2 is an unsubstituted unbranched saturated C 1 -C 4 In embodiments, R 2 is an unsubstituted unbranched saturated C 1 -C 2 It is an alkyl.

[0241] In embodiments, R 2 is an unsubstituted unbranched unsaturated alkyl (e.g., C 1 -C 25 , C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 In an embodiment, R 2 is an unsubstituted unbranched unsaturated C 1 -C 25In embodiments, R 2 is an unsubstituted unbranched unsaturated C 1 -C 20 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 1 -C 12 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 1 -C 8 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 1 -C 6 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 1 -C 4 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 1 -C 2 It is an alkyl.

[0242] In embodiments, R 2 is unsubstituted C 9 -C 19 In embodiments, R 2 is an unsubstituted branch C 9 -C 19 In embodiments, R 2 is an unsubstituted unbranched C 9 -C 19 In embodiments, R 2 is an unsubstituted branched saturated C 9 -C 19 In embodiments, R 2 is an unsubstituted branched unsaturated C 9 -C 19 In embodiments, R 2 is an unsubstituted unbranched saturated C 9 -C 19 In embodiments, R 2 is an unsubstituted unbranched unsaturated C 9 -C 19 It is an alkyl.

[0243] In embodiments, R 3 is hydrogen, -NH2 , -OH, -SH, -C(O)H, -C(O)NH 2 , -NHC(O)H, -NHC(O)OH, -NHC(O)NH 2 , -C(O)OH, -OC(O)H, -N 3 , substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted alkyl (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heteroalkyl (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted cycloalkyl (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted heterocycloalkyl (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent), or unsubstituted aryl (e.g., C 6 -C 12 , C 6 -C 10, or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted), or unsubstituted heteroaryl (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 3 is hydrogen, -NH 2 , -OH, -SH, -C(O)H, -C(O)NH 2 , -NHC(O)H, -NHC(O)OH, -NHC(O)NH 2 , -C(O)OH, -OC(O)H, -N 3 , substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) alkyl (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heteroalkyl (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) cycloalkyl (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) heterocycloalkyl (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), substituted (e.g., substituted with a substituent, a size-limited substituent, or a lower substituent) aryl (e.g., C 6 -C 12 , C 6 -C 10, or phenyl), or substituted (e.g., substituted, size-limited, or lower substituted) heteroaryl (e.g., 5-12 membered ring, 5-10 membered ring, 5-9 membered ring, or 5-6 membered ring). 3 is hydrogen, -NH 2 , -OH, -SH, -C(O)H, -C(O)NH 2 , -NHC(O)H, -NHC(O)OH, -NHC(O)NH 2 , -C(O)OH, -OC(O)H, -N 3 , unsubstituted alkyl (e.g., C 1 -C 20 , C 1 -C 12 , C 1 -C 8 , C 1 -C 6 , C 1 -C 4 , or C 1 -C 2 ), unsubstituted heteroalkyl (e.g., 2-20 membered ring, 2-12 membered ring, 2-8 membered ring, 2-6 membered ring, 4-6 membered ring, 2-3 membered ring, or 4-5 membered ring), unsubstituted cycloalkyl (e.g., C 3 -C 10 , C 3 -C 8 , C 3 -C 6 , C 4 -C 6 , or C 5 -C 6 ), unsubstituted heterocycloalkyl (e.g., 3-10 membered ring, 3-8 membered ring, 3-6 membered ring, 4-6 membered ring, 4-5 membered ring, or 5-6 membered ring), unsubstituted aryl (e.g., C 6 -C 12 , C 6 -C 10 , or phenyl), or unsubstituted heteroaryl (e.g., a 5-12 membered ring, a 5-10 membered ring, a 5-9 membered ring, or a 5-6 membered ring). 3 If is substituted, R 3 is substituted with a substituent. In embodiments, R 3 If is substituted, R 3is substituted with size-limited substituents. In embodiments, R 3 If is substituted, R 3 is substituted with a lower substituent.

[0244] In embodiments, the lipid-modified nucleic acid compound comprises a motif described herein, including those of any aspect, embodiment, claim, drawing (e.g., Figures 1-83, particularly Figures 1-12, and Figures 80-83), table (e.g., Table 1), example, or scheme (e.g., Schemes I, II, and III). In embodiments, the lipid-modified nucleic acid compound comprises a motif selected from any one of the motifs in Table 1 below. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-01 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-03 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-06 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-07 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-08 motif in Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-09 motif in Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-11 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-12 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-13 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-30 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-31 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-32 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-33 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-34 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-35 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-36 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-39 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-43 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-44 motif of Table 1.In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-45 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-46 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-50 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-51 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-52 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-53 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-54 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-55 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-03-06 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-03-50 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-03-51 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-03-52 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-03-53 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-03-54 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-03-55 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-04-01 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-05-01 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-06-06 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-06-50 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-06-51 motif of Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-06-52 motif of Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-06-53 motif of Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-06-54 motif of Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-06-55 motif of Table 1.In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-08-01 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-09-01 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-10-01 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-11-01 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-60 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-61 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-62 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-63 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-64 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-65 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-66 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-67 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-68 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-69 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-70 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-71 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-72 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-73 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-74 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-75 motif from Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-76 motif of Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-77 motif of Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-78 motif of Table 1. In embodiments, the lipid-modified nucleic acid compound comprises a DTx-01-79 motif of Table 1.In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-80 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-81 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-82 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-83 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-84 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-85 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-86 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-87 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-88 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-89 motif from Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-90 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-91 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-92 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-93 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-94 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-95 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-96 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-97 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-98 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises a DTx-01-99 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises the DTx-01-100 motif of Table 1. In an embodiment, the lipid-modified nucleic acid compound comprises the DTx-01-101 motif of Table 1.

[0245] In the embodiment of the compound having the structure of formula I, Ia, Ib, II, IIa, IIb, III, IIIa or IIIb, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the compound at any of its 3'-ends.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety at the 3'-end of its guide strand.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety at the 3'-end of its passenger strand.

[0246] In the embodiment of the compound having the structure of formula I, Ia, Ib, II, IIa, IIb, III, IIIa or IIIb, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the compound at either of its 5'-end.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety at the 5'-end of its guide strand.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety at the 5'-end of its passenger strand.

[0247] In embodiments having the structure of formula I, Ia, Ib, II, IIa, or IIb, conjugation to the 3' end occurs via a phosphodiester bond. In embodiments having the structure of formula I, Ia, Ib, II, IIa, or IIb, conjugation to the 5' end occurs via a phosphodiester bond.

[0248] In an embodiment of Formula III, IIIa, or IIIb, A is a modified double-stranded oligonucleotide and Z 1 is conjugated to the 3' end of the passenger strand of a modified double-stranded oligonucleotide, Z 2 is conjugated to the 5' end of the passenger strand of a modified double-stranded oligonucleotide.

[0249] In an embodiment of Formula III, IIIa, or IIIb, A is a modified double-stranded oligonucleotide and Z 1is conjugated to the 3' end of the guide strand of a modified double-stranded oligonucleotide, Z 2 is conjugated to the 5' end of the passenger strand of a modified double-stranded oligonucleotide.

[0250] In embodiments, provided herein is a method of introducing a modified double-stranded oligonucleotide into a cell in vitro by contacting the cell with a lipid-conjugated compound of formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or a corresponding pharma- ceutically acceptable salt thereof, under free uptake conditions. In embodiments, the compound is in direct contact with the cell. In embodiments, the cell is a mammalian cell. In embodiments, the cell is a human cell. In embodiments, the cell is a mouse cell. In embodiments, the cell is a fibroblast cell. In embodiments, the cell is an NIH3T3 cell. In embodiments, the cell is a kidney cell. In embodiments, the cell is a HEK293 cell. In embodiments, the cell is an endothelial cell. In embodiments, the cell is a HUVEC cell. In embodiments, the cell is an adipose cell. In embodiments, the cell is a differentiated 3T3L1 cell. In embodiments, the cell is a macrophage cell. In embodiments, the cell is a RAW264.7 cell. In embodiments, the cell is a neuronal cell. In embodiments, the cell is a primary rat neuron. In embodiments, the cell is a SH-SY5Y cell. In embodiments, the cell is a muscle cell. In embodiments, the cell is a differentiated primary human musculoskeletal cell. In embodiments, the cell is a trabecular meshwork cell. In embodiments, the cell may be from an immortalized cell line. In embodiments, the cell may be from a primary cell. In embodiments, the cell is an adipocyte cell. In embodiments, the cell is a human adipocyte cell. In embodiments, the cell is a hepatocyte cell. In embodiments, the cell is a human hepatocyte cell. In embodiments, the cell is a T cell.

[0251] In an embodiment, provided herein is a method of introducing modified double-stranded oligonucleotides into cells in vivo by intravitreal injection of lipid-conjugated compounds of formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or their corresponding pharma- ceutically acceptable salts. In an embodiment, the cells are ocular cells. In an embodiment, the ocular cells are photoreceptors, bipolar cells, ganglion cells, horizontal cells, amacrine cells, corneal epithelial cells, corneal endothelial cells, and corneal stromal cells. In an embodiment, the corneal epithelial cells are basal cells, wing cells, or squamous cells.

[0252] In embodiments, provided herein is a method of introducing a modified double-stranded oligonucleotide into a cell in vivo by intrathecal administration. In embodiments, provided herein is a method of introducing a modified double-stranded oligonucleotide into a cell by intraventricular administration.

[0253] In embodiments, provided herein are methods of introducing modified double-stranded oligonucleotides into cells in vivo by contact with systemic administration of a lipid-conjugated compound of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or its corresponding pharma- ceutically acceptable salt.

[0254] In embodiments, provided herein is a method of introducing a lipid-conjugated compound of formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or any of its corresponding pharma- ceutically acceptable salts, into a cell. In embodiments, the cell is in vitro. In embodiments, the cell is ex vivo. In embodiments, the cell is in vivo.

[0255] In embodiments, provided herein are methods of administering a lipid-conjugated compound of formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or any of its corresponding pharma- ceutically acceptable salts, to a subject. The subject may have a disease or disorder of the eye, brain, liver, kidney, heart, adipose tissue, lung, muscle, or spleen.

[0256] In embodiments, the eye disease or disorder is blepharitis, cataracts, chalazion, conjunctivitis, diabetic retinopathy, dry eye, glaucoma, keratitis, keratoconus, macular degeneration, ocular allergy, ocular hypertension, pinguecula, presbyopia, pterygium, retinoblastoma, subconjunctival hemorrhage, or uveitis.

[0257] In embodiments, the disease or disorder is a neurological disease or disorder, a metabolic disease or disorder, an inflammatory disease or disorder, hi embodiments, the subject has cancer.

[0258] In any of the in vivo administration or subject-related embodiments, administration is systemic, which may include, but is not limited to, subcutaneous, intravenous, intramuscular, and oral administration. In any of the in vivo administration or subject-related embodiments, administration is local, which may include, but is not limited to, intravitreal, intrathecal, and intraventricular administration.

[0259] In an embodiment, a method for introducing modified double-stranded oligonucleotide ex vivo is provided herein, comprising contacting a cell with a compound of formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or its corresponding pharma- ceutically acceptable salt, under free uptake conditions.In an embodiment, the cell is a neuron, a TBM cell, a skeletal muscle cell, a fat cell, or a hepatocyte.

[0260] In embodiments, provided herein is a cell containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or a corresponding pharma- ceutically acceptable salt thereof. In embodiments, the cell is a mammalian cell. In embodiments, the cell is a human cell. In embodiments, the cell is a mouse cell. In embodiments, the cell is a fibroblast cell. In embodiments, the cell is an NIH3T3 cell. In embodiments, the cell is a kidney cell. In embodiments, the cell is a HEK293 cell. In embodiments, the cell is an endothelial cell. In embodiments, the cell is a HUVEC cell. In embodiments, the cell is an adipose cell. In embodiments, the cell is a differentiated 3T3L1 cell. In embodiments, the cell is a macrophage cell. In embodiments, the cell is a RAW264.7 cell. In embodiments, the cell is a neuronal cell. In embodiments, the cell is a primary rat neuron. In embodiments, the cell is a SH-SY5Y cell. In embodiments, the cell is a muscle cell. In embodiments, the cell is a differentiated primary human musculoskeletal cell. In embodiments, the cell is a trabecular meshwork cell. In embodiments, the cell may be from an immortalized cell line. In embodiments, the cell may be from a primary cell. In embodiments, the cell is an adipocyte cell. In embodiments, the cell is a human adipocyte cell. In embodiments, the cell is a hepatocyte cell. In embodiments, the cell is a human hepatocyte cell. In embodiments, the cell is a primary human adipocyte cell. In embodiments, the cell is a primary HUVEC cell. In embodiments, the cell is a primary human hepatocyte cell.

[0261] In embodiments, the cells are treated with a compound having the structure of Formula III: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide has a Z at the 3' end of one strand of the modified double-stranded oligonucleotide or the Z at the 3' end of the modified single-stranded oligonucleotide. 1 Conjugated to Z 1 but [ka] and The modified double-stranded oligonucleotide may have a Z at the 5' end of one strand of the modified double-stranded oligonucleotide or at the 5' end of the modified single-stranded oligonucleotide. 2 Conjugated to Z 2 but, [ka] The compound contains a compound,

[0262] In embodiments, the cells are treated with a compound having the structure of Formula IIIa: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide has a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or at the 3' end of the modified single-stranded oligonucleotide. [ka] and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or the 5' end of the modified single-stranded oligonucleotide. [ka] The compound is conjugated to

[0263] In embodiments, the cells are treated with a compound having the structure of Formula IIIb: [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide has a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or at the 3' end of the modified single-stranded oligonucleotide. [ka] and the modified double-stranded or single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or at the 5' end of the modified single-stranded oligonucleotide. [ka] The compound is conjugated to

[0264] In an embodiment of the cell containing a compound having the structure of formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, the cell is a mammalian cell. In an embodiment, the cell is a human cell. In an embodiment, the cell is an endothelial cell. In an embodiment, the cell is a HUVEC cell.

[0265] In the embodiment of the cell containing the compound having the structure of formula I, Ia, Ib, II, IIa, IIb, III, IIIa or IIIb, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the compound at any of its 3'-ends.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety at the 3'-end of its guide strand.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety at the 3'-end of its passenger strand.

[0266] In embodiments of cells containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, conjugation occurs via a phosphodiester bond.

[0267] In the embodiment of the cell containing the compound having the structure of formula I, Ia, Ib, II, IIa, IIb, III, IIIa or IIIb, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the compound at either of its 5'-end.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety at the 5'-end of its guide strand.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety at the 5'-end of its passenger strand.

[0268] In embodiments of cells containing a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, conjugation occurs via a phosphodiester bond.

[0269] In an embodiment, provided herein is a method for introducing a modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells in vitro, comprising contacting the cells with a compound having the structure of Formula I, Ia, Ib, II, IIa, IIb, III, IIIa, or IIIb, or a corresponding pharma- ceutically acceptable salt thereof, under free uptake conditions. In an embodiment of this method, the compound is [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide has a Z at the 3' end of one strand of the modified double-stranded oligonucleotide or the Z at the 3' end of the modified single-stranded oligonucleotide. 1 Conjugated to Z 1 but, [ka] and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide is a modified double-stranded oligonucleotide having a Z at the 5' end of one strand of the modified double-stranded oligonucleotide or a Z at the 5' end of the modified single-stranded oligonucleotide. 2 Conjugated to Z 2 but, [ka] The method provided herein is

[0270] In an embodiment of this method, the compound is [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide comprises a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or at the 3' end of the modified single-stranded oligonucleotide. [ka] and the modified double-stranded or single-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or at the 5' end of the modified single-stranded oligonucleotide. [ka] is conjugated to

[0271] In an embodiment of this method, the compound is [ka] or a pharma- ceutically acceptable salt thereof, wherein A is a modified double-stranded oligonucleotide or a modified single-stranded oligonucleotide, and the modified double-stranded oligonucleotide or the modified single-stranded oligonucleotide comprises a lipid-containing moiety at the 3' end of one strand of the modified double-stranded oligonucleotide or at the 3' end of the modified single-stranded oligonucleotide. [ka] and the modified double-stranded oligonucleotide is conjugated to a lipid-containing moiety at the 5' end of one strand of the modified double-stranded oligonucleotide or at the 5' end of the modified single-stranded oligonucleotide. [ka] is conjugated to

[0272] In an embodiment of the method of introducing modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells in vitro, the method comprises contacting cells with a compound having the structure of formula III, IIIa, or IIIb under free uptake conditions, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the compound at either of its 3'-ends.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the compound at the 3'-end of its guide strand.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the passenger strand at the 3'-end of its passenger strand.

[0273] In an embodiment of a method of introducing a modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells in vitro, comprising contacting the cells with a compound having the structure of Formula III, IIIa, or IIIb under free uptake conditions, conjugation occurs via a phosphodiester bond.

[0274] In an embodiment of the method of in vitro introduction of modified double-stranded oligonucleotide into human umbilical vein endothelial cells, NIH3T3 cells, RAW264.7 cells, HEK293 cells, or SH-SY5Y cells, the method comprises contacting cells with a compound having the structure of formula III, IIIa, or IIIb under free uptake conditions, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the compound at either of its 5'-ends.In an embodiment, the modified double-stranded oligonucleotide is conjugated to the lipid-containing moiety of the compound at the 5'-end of its guide strand.In an embodiment, the modified double-stranded oligonucleotide is conjugate...

Claims

1. The following structure: 【Chemistry 1】 (In the formula, A is an oligonucleotide; L 3 But independently, -OPO 2 -O-, L 4 But independently, 【Chemistry 3】 and L 5 is independently -L 5A -L 5B -L 5C -L 5D -L 5E - and L 5A is independently a bond or unsubstituted alkylene; L 5B is independently a bond, —NHC(O)—, or unsubstituted phenylene; L 5C is independently a bond, unsubstituted alkynylene, or unsubstituted phenylene; L 5D is independently a bond or unsubstituted alkylene; L 5E is -NHC(O)-, L 6 is independently -L 6A -L 6B -L 6C -L 6D -L 6E - and L 6A is, independently, a bond, L 6B is -NHC(O)-, L 6C is independently a bond, unsubstituted alkynylene, or unsubstituted phenylene; L 6D is independently a bond or unsubstituted alkylene; L 6E is independently a bond or -NHC(O)-; R 1 and R 2 is independently an unsubstituted C 1 -C 25 alkyl, where R 1 and R 2 At least one of the groups is unsubstituted C 9 -C 19 is alkyl, R 3 are independently hydrogen; and t is an integer from 1 to 5, or a pharma- ceutically acceptable salt thereof, A is a double-stranded or single-stranded oligonucleotide; One L 3 is attached to the 3' carbon of said double stranded or single stranded oligonucleotide; One L 3 is attached to the 5' carbon of said double stranded or single stranded oligonucleotide; and / or One L 3 is connected to the nucleobase of the double stranded oligonucleotide or single stranded oligonucleotide; A compound or a pharma- ceutically acceptable salt thereof.

2. 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, wherein t is 1, 2, or 3.

3. 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt thereof, wherein A is a double-stranded oligonucleotide.

4. 4. The compound of claim 3, or a pharma- ceutically acceptable salt thereof, wherein the double-stranded oligonucleotide of A is modified.

5. The compound according to claim 4 or a pharma- ceutically acceptable salt thereof, wherein the double-stranded oligonucleotide is an siRNA.

6. 6. The compound of claim 5 or a pharma- ceutically acceptable salt thereof, wherein the siRNA comprises a guide strand and a passenger strand.

7. 3. The compound of claim 1 or 2, or a pharma- ceutically acceptable salt thereof, wherein A is a single-stranded oligonucleotide.

8. 8. The compound of claim 7, or a pharma- ceutically acceptable salt thereof, wherein the single-stranded oligonucleotide of A is modified.

9. One L 3 is attached to the 3' carbon of the guide strand of the double-stranded oligonucleotide, or a pharma- ceutically acceptable salt thereof.

10. One L 3 is attached to the 3' carbon of the passenger strand of the double-stranded oligonucleotide, or a pharma- ceutically acceptable salt thereof.

11. One L 3 is attached to the 5' carbon of the passenger strand of the double-stranded oligonucleotide, or a pharma- ceutically acceptable salt thereof.

12. -L 3 -L 4 --But independently, 【Chemistry 5】 and attached to the 3' carbon of said double stranded or single stranded oligonucleotide; and / or 【Chemistry 6】 and is attached to the 5' carbon of said double stranded or single stranded oligonucleotide; 12. The compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof.

13. L 6 is independently -NHC(O)-, or a pharma- ceutically acceptable salt thereof.

14. L 5 But independently, 【Chemistry 9】 14. The compound according to any one of claims 1 to 13, wherein:

15. R 1 is independently an unsubstituted C 11 -C 17 15. The compound according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.

16. R 2 is unsubstituted C 1 -C 17 16. The compound of any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.

17. the oligonucleotide is an siRNA, a microRNA mimic, a stem-loop structure, a single stranded siRNA, an RNase H oligonucleotide, an anti-microRNA oligonucleotide, a steric hindrance oligonucleotide, a CRISPR guide RNA, or an aptamer; The oligonucleotide is modified, the oligonucleotide comprises a nucleotide analogue, and / or the oligonucleotide comprises a locked nucleic acid (LNA) residue, a bicyclic nucleic acid (BNA) residue, a constrained ethyl (cEt) residue, an unlocked nucleic acid (UNA) residue, a phosphorodiamidate morpholino oligomer (PMO) monomer, a peptide nucleic acid (PNA) monomer, a 2'-O-methyl (2'-OMe) residue, a 2'-O-methyoxyethyl residue, a 2'-deoxy-2'-fluoro residue, a 2'-O-methoxyethyl / phosphorothioate residue, a phosphoramidate, a phosphorodiamidate, a phosphorothioate, a phosphorodithioate, a phosphonocarboxylic acid, a phosphonocarboxylate, a phosphonoacetic acid, a phosphonoformic acid, a methyl phosphonate, a boron phosphonate, or an O-methyl phosphoramidite; 17. The compound according to any one of claims 1 to 16, or a pharma- ceutically acceptable salt thereof.

18. A cell comprising the compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof.

19. The cell of claim 18 , wherein the cell is a primary cell or an immortalized cell.

20. 20. The cell of claim 19, wherein the cell is an adipocyte cell, a hepatocyte cell, a fibroblast cell, an endothelial cell, a kidney cell, a human umbilical vein endothelial cell (HUVEC), an adipose cell, a macrophage cell, a neuron cell, a muscle cell, or a differentiated primary human skeletal muscle cell.

21. The cell of claim 19, wherein the cell is an NIH3T3 cell, a differentiated 3T3L1 cell, a RAW264.7 cell, or an SH-SY5Y cell.

22. A method for introducing an oligonucleotide into a cell in vitro, comprising contacting said cell under free uptake conditions with a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.

23. 23. The method of claim 22, wherein the method is ex vivo and the cells are primary cells.

24. 24. The method of claim 23, wherein the cell is an adipocyte cell, a hepatocyte cell, a fibroblast cell, an endothelial cell, a kidney cell, a human umbilical vein endothelial cell (HUVEC), an adipose cell, a macrophage cell, a neuronal cell, a rat neuron, a muscle cell, or a differentiated primary human skeletal muscle cell.

25. 23. The method of claim 22, wherein the cell is an immortalized cell.

26. The method of claim 25, wherein the cell is a NIH3T3 cell, a differentiated 3T3L1 cell, a RAW264.7 cell, or a SH-SY5Y cell.

27. 20. A method for introducing an oligonucleotide into a cell ex vivo, comprising obtaining a cell and contacting said cell under free uptake conditions with a compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.

28. 28. The method of claim 27, wherein the cell is a neuron, a TBM cell, a skeletal muscle cell, an adipocyte cell, a hepatocyte cell, or a human umbilical vein endothelial cell.

29. A method comprising contacting a cell in vitro or ex vivo with a compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof.

30. A pharmaceutical composition for treating a subject, comprising a compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof.

31. 31. The pharmaceutical composition of claim 30, wherein the subject has a disease or disorder of the eye, liver, kidney, heart, adipose tissue, lung, muscle, or spleen.

32. A pharmaceutical composition for introducing an oligonucleotide into a cell in a subject, comprising a compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof.

33. A cell comprising a compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof.

34. A pharmaceutical composition comprising a pharma- ceutically acceptable excipient and a compound according to any one of claims 1 to 17 or a pharma- ceutically acceptable salt thereof.

Citation Information

Patent Citations

  • Carbohydrate conjugates as oligonucleotide delivery agents

    JP2011505425A

  • Sphingosine-bound siRNA

    US20120142765A1

  • Oligomer-conjugate complexes and their use

    US20150018540A1

  • Ether lipid-nucleoside covalent conjugates

    US5512671A

  • Base-protected oligonucleotide

    WO2013122236A1